Entries |
Document | Title | Date |
20080199499 | Method for Making Targeted Therapeutic Agents - Provided herein are methods and kits for making a targeted therapeutic for treating a disease or condition. The therapeutic agents can be targeted to patient-specific disease markers. In one of these methods, the method includes obtaining a biological sample from a patient having the disease or condition, or who is at risk for developing the disease or condition. In this particular method, the sample includes a population of diseased cells, screening a library comprising proteins linked to their cognate mRNAs to identify mRNA-protein pairs that bind to the diseased cells, isolating one or more proteins from the identified mRNA-protein pairs, and conjugating the isolated protein(s) to a therapeutic agent. Some of the methods further include preparing a library with proteins linked to their cognate mRNAs. In certain of these methods, the preparation of the library includes providing at least two candidate mRNA molecules in which each of the mRNA molecules includes a cross-linker, translating at least two of the candidate mRNA molecules to generate at least one translated protein, and linking at least one of the candidate mRNA molecules to its corresponding translated protein via the cross-linker to form at least one cognate pair. | 08-21-2008 |
20080226680 | Method and composition for delivery of medicants to animals - According to the present invention, a vaccine or pharmaceutical-containing composition is applied to the muzzle area of the animal, which will then naturally use its tongue to clean itself. This behavior will cause the animal to deposit applied composition to the mucosa of the nasal and oral cavities, thus meeting the need for a simple, effective, and efficient vaccination or treatment method. | 09-18-2008 |
20080226681 | Highly Active Glycoproteins-Process Conditions and an Efficient Method for their Production - The present invention relates to highly active glycoproteins with specific sialylation degrees, a pharmaceutical composition for use in diagnosis or therapy comprising the glycoproteins, a method for the determination of highly active glycoproteins and of the conditions for their production, a method for producing the highly active glycoproteins, and a method for differential sialylation of secretory glycoproteins. The invention also relates to the use of the recombinantly expressed highly active glycoproteins for biological purposes and for prophylactic and/or therapeutic treatment or diagnosis of diseases, particularly bone marrow transplantation, neutropenia, cytopenia, AML and myelodysplastic syndromes, cancer, HIV and/or diseases of hematopoietic systems. | 09-18-2008 |
20080226682 | Immunoactive Compositions for Improved Oral Delivery of Vaccines and Therapeutic Agents - The present invention concerns methods and compositions for improved oral delivery of bioactive agents, such as vaccines. In preferred embodiments, the compositions comprise at least one lectin, saponin, polyunsaturated fatty acid and/or isoflavone. In further embodiments, the compositions may further comprise at least one protease inhibitor, buffer and/or surfactant. In more preferred embodiments, the lectins, saponins, fatty acids, isoflavones and/or protease inhibitors may be derived from extracts, homogenates, finely ground powders or derivatives of plant or animal material, such as beans, nuts, peas, fish meal or krill. The relative amounts of various naturally occurring materials contained in the compositions may be selected to optimize the concentrations of one or more lectins, saponins, polyunsaturated fatty acids and/or isoflavones. The compositions are of use for oral delivery of a wide variety of bioactive agents, particularly protein or peptide based agents. | 09-18-2008 |
20080226683 | Pharmaceutical Composition Including Clinoptilolite - The invention is for a method of potentiating clinoptilolite, the method including the steps of: providing fresh or spent clinoptilolite; exposing the clinoptilolite to a saline solution having a sodium ion content of about 10% to liberate impurities from the clinoptilolite; and drying the washed clinoptilolite fraction to render a potentiated clinoptilolite fraction. Preferably, the clinoptilolite is exposed to the saline solution for a period of about 48 hours. The washed clinoptilolite may be dried by filtered, heated air. This allows an optimal cation exchange capacity of the clinoptilolite to be reached. The clinoptilolite has uses as a medicament for a variety of aliments. | 09-18-2008 |
20080241196 | Artificial invaplex - An artificial invasin complex is prepared from purified or recombinantly prepared invasins and gram negative bacteria lipopolysaccharides. Typically, IpaB is mixed with IpaC to form a IpaB:IpaC complex. This invasin protein complex is then mixed with the lipopolysaccharide to form an artificial invasin complex. Additional bioactive molecules can be incorporated into the complex during manufacture. This artificial invasin complex is similar in function to native Invaplex 24 or Invaplex 50. The artificial invasin complex has superior immunogenicity properties relative to the native complex and can be taylor made. Its method of preparation lends itself to scale up. The artificial invasin complex can facilitate transport of biomolecules, therapeutics and antibiotics across cell membranes in a manner similar to native Shigella Invaplex. | 10-02-2008 |
20080254072 | Method For Inhibiting Scavenger Receptor-A and Increasing Immune Response to Antigens - Provided is a method for enhancing an immune response to a desired antigen in an individual. The method is performed by administering to the individual an agent capable of inhibiting class A macrophage scavenger receptor (SR-A) and optionally administering the desired antigen. Also provided is a method for enhancing an immune response to an antigen by administering to an individual a composition containing antigen presenting cells that are characterized by specifically inhibited SR-A. Substantially purified populations of mammalian dendritic cells characterized by specifically inhibited SR-A are also provided. | 10-16-2008 |
20080268000 | Vaccine Stabilising Formula with Live Antigens for Use in Mass Vaccination Systems - The invention relates to a vaccine stabilizing formula with live antigens for use in mass medication and vaccination systems which are used in animal protein production processes. The invention comprises a product in the form of a powder or liquid to enable the same to be solubilized in water formed by a homogeneous mixture of compounds of organic and inorganic origin. The invention can be used to stabilize the critical physicochemical parameters of the water upon vaccination (pH, hardness and presence of disinfectants), thereby reducing the microbial and viral liter loss of the vaccine caused by environmental exposure upon vaccination. The inventive formula is intended to be used in drinking water medication and vaccination systems and in spray medication and vaccination systems. | 10-30-2008 |
20080286316 | Lipid raft, caveolin protein, and caveolar function modulation compounds and associated synthetic and therapeutic methods - The present invention is directed to the modulation of lipid rafts, caveolin proteins, or caveolar functions and processes by platinum(IV) compounds. Caveolae and/or lipid rafts are associated with cell transcription regulation, membrane and cellular transport, cell membrane receptor function, cellular trafficking, antigen presentation, cell differentiation and activation, cytokine modulation, membrane structure and function, and protein modulation. Caveolae, caveolin proteins and lipid rafts are known therapeutic targets for numerous biological functions. Diseases and disorders currently known to be therapeutically targeted through caveolae and/or lipid rafts include diabetes, cancer, cardiovascular diseases, atherosclerosis, pulmonary fibrosis, multiple sclerosis, viral and prion diseases, neuronal disorders, degenerative muscular dystrophies, and autoimmune disorders. | 11-20-2008 |
20090004227 | Peroral Vaccine Carrier System - The present invention provides a system in which a recombinant plant expressing a target peptide is orally administered to thereby achieve exertion of the function of the peptide, along with the genetically recombinant plant, and the present invention relates to a carrier system for oral administration of a target peptide by oral administration of a plant (potato) that expresses a target peptide by expressing for example a fused gene obtained by fusing the LRE1 gene coding for the immunogenic peptide LRE1 derived from the | 01-01-2009 |
20090017077 | Compounds and methods for immunotherapy and diagnosis of tuberculosis - Compounds and methods for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more | 01-15-2009 |
20090041809 | DOUBLE-STRANDED LOCKED NUCLEIC ACID COMPOSITIONS - Immunostimulatory agents, including nucleic acids having one or more than one locked nucleic acid (LNA) nucleosides are provided. The nucleic acids may further comprise CpG motifs. The nucleic acids may be double stranded, and may comprise dsRNA. | 02-12-2009 |
20090081259 | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect - The present invention relates to the treatment of individuals diagnosed with multiple sclerosis, emotional lability or pseudobulbar affect comprising administering to said individual an effective amount of a 1-aminocyclohexane derivative, namely memantine or neramexane. | 03-26-2009 |
20090092641 | USES OF NATURAL IMMUNOBIOTIC EXTRACT - The present invention provides a method of improving disease management in an animal by administering an effective amount of β-glucan composition to the animal. The β-glucan composition comprises at least about 70% β-(1,3/1,6)-D-glucan by dry weight and a biological activity of at least 20 μg Bb released per mg of β-(1,3/1,6)-D-glucan. The method may also result in beneficial secondary effects including an increase in growth efficiency of the animal; an increase in the survival rate of the animal; an increase in the colostrum quality of the animal; and any combination thereof. The β-glucan composition may also be administered in combination with or prior to a vaccine, leading to an increase in antibody formation; the negative growth responses associated with administration of a vaccine may also be reduced. In the present method, the β-glucan composition may be administered in combination with an animal feed. | 04-09-2009 |
20090148479 | METHODS OF MODULATING AN IMMUNE RESPONSE USING IMMUNOSTIMULATORY SEQUENCES AND COMPOSITIONS FOR USE THEREIN - The invention provides methods of modulating an immune response to a second antigen which entail administration of a first antigen and an immunostimulatory polynucleotide. Modulation of the immune response is generally manifested as stimulation of a Th1 response. | 06-11-2009 |
20100003288 | CpG DNA Adjuvant in Avian Vaccines - A CpG DNA adjuvant in avian vaccines is disclosed, which includes an immunostimulatory oligodeoxynucleotide (ODN) having a plurality of TCG tandem repeats at a 5′end, a poly-G structure at a 3′ end, and at least one unmethylated CpG motif with avian specific flanking sequences at two ends thereof between the 5′ end and the 3′ end. The CpG DNA adjuvant in avian vaccines is advantageous to carry out large-scale production, specifically enhance avian innate and adaptive immune responses, and the CpG DNA adjuvant is hardly to be digested by DNase due to its particular structures. | 01-07-2010 |
20100098730 | IMMUNOGLOBULIN VARIANTS AND USES THEREOF - Variant immunoglobulins with one or more amino acid modifications in the Fc region that have increased in vivo half-lives, and methods of using the same are provided. | 04-22-2010 |
20100112012 | MODULATION OF IMMUNE RESPONSES - Compositions and methods for modulating an NF- | 05-06-2010 |
20100119556 | METHODS AND COMPOSITIONS FOR MODULATING AN IMMUNE RESPONSE WITH IMMUNOGENIC OLIGONUCLEOTIDES - This document relates to compositions and methods for modulating an immune response. For example, compositions of immunostimulatory CpG oligonucleotides derived from retroviral genomes are provided. | 05-13-2010 |
20100166805 | Modulation of immunostimulatory properties by small oligonucleotide-based compounds - The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3′ ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5′ end. | 07-01-2010 |
20100203087 | CHEMOREPULSION OF CELLS - The present invention provides compositions and methods of controlling the direction and/or movement of migratory cells. Specifically, the invention is directed to the identification of novel chemorepellents and unimodal fugetaxins, their agonists and antagonists which alter or affect the movement of cells involved in immune, inflammatory or cancerous phenotypes. | 08-12-2010 |
20100233216 | USE OF MICROVESICLES (MVS) FOR PREPARING A MEDICAMENT HAVING ADJUVANT ACTIVITY ON ENDOTHELIAL CELL TRANSPLANTATION, PARTICULARLY IN THE TREATMENT OF DIABETES BY PANCREATIC ISLET TRANSPLANTATION, AND RELATED METHOD - The invention relates to the use of microvesicles derived from cells of the endothelial cell lineage, preferably from endothelial progenitor cells, as an adjuvant agent in endothelial cell-pancreatic islet transplantation, particularly in the treatment of type I or type II diabetes by pancreatic islet transplantation. The adjuvant effect of the microvesicles consists in the improvement of survival and functionality of the transplanted islets. The adjuvant effect of the microvesicles is maintained even when the recipient is subjected to rapamycin-based immunosuppression. | 09-16-2010 |
20100239615 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF LUNG CANCER - Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer. | 09-23-2010 |
20100247581 | EDIBLE PRODUCT HAVING AN IMMUNOSTIMULATING EFFECT - There is provided an edible product having an immunostimulating effect, said product comprising immunostimulating polysaccharides obtainable from plants of the Asclepiadoideae subfamily. Also provided is a process for preparing such an edible product and a composition comprising from 0.0001 to 25% by weight of polysaccharides having an immunostimulating effect. | 09-30-2010 |
20100255040 | COMPOSITION FOR IMPROVING TLR-MEDIATED CELLULAR IMMUNITY COMPRISING POLY-GAMMA-GLUTAMIC ACID - The present invention relates to a composition for improving cellular immunity, which comprises an effective dose of poly-gamma-glutamic acid, and more particularly, to a composition for improving cellular immunity comprising poly-gamma-glutamic acid, which has effects of inducing enhancement of TLR-mediated Th1 cellular immunity and improving antigen presenting activity to maintain the improved activity. The inventive composition comprising an effective dose of poly-gamma-glutamic acid has very little toxicity and side effects, and can be added to a vaccine composition for preventing and treating animal viral or bacterial infections and cancer, or a vaccine composition for preventing and treating human viral or bacterial infections and cancer to show cellular immunity-enhancing effects. | 10-07-2010 |
20100285072 | Method for Producing Dendritic Cells - The present invention relates to a method for producing dendritic cells and their use in medicaments by genetic engineering aimed at functionally improving their therapeutic efficacy in the treatment of cancer, microbial infections, allergies, auto-immune diseases or organ and stem cell transplant rejection. | 11-11-2010 |
20100316676 | Bisphosphonate Compounds and Methods for Bone Resorption Diseases, Cancer, Bone Pain, Immune Disorders, and Infectious Diseases - Bisphosphonate compounds and related methods of making and using are disclosed, including pyridinium-1-yl, quinolinium-1-yl, and related compounds. The activity of compounds is disclosed in the context of functional assays such as | 12-16-2010 |
20100322976 | TONIC AND FOOD SUPPLEMENT COMPRISING ALOE VERA AND HONEY - A mixture of honey (preferably manuka honey) with aloe vera extract is concentrated for distribution and then diluted before use as a tonic or food supplement for mammals, particular those with compromised or poorly performing immune systems. In particular (though without limit) the composition is useful in the control of chronic mastitis in dairy cows. | 12-23-2010 |
20110008393 | NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 58P1D12 USEFUL IN TREATMENT AND DETECTION OF CANCER - A novel gene 58P1D12 and its encoded protein, and variants thereof, are described wherein 58P1D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 58P1D12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 58P1D12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 58P1D12 can be used in active or passive immunization. | 01-13-2011 |
20110008394 | ACTIVE SUBSTANCES THAT INCREASE THE ACTIVATION THRESHOLD OF IMMUNE CELLS - The present invention relates to the use of active substances that increase the activation threshold of immune cell as an active principle for the preparation of a cosmetic or pharmaceutical composition, especially a dermatological composition. The invention also relates to a method for screening such active substances. | 01-13-2011 |
20110014242 | PROMOTERS FOR EXPRESSION IN MODIFIED VACCINIA VIRUS ANKARA - The invention concerns promoters, in particular for the expression of genes and/or coding sequences in vaccinia viruses such as Modified vaccinia virus Ankara (MVA). The invention further concerns expression cassettes comprising said promoter, vectors comprising said expression cassettes as well as pharmaceutical compositions and vaccines. | 01-20-2011 |
20110045027 | Adjuvant - The present invention provides a novel adjuvant for polynucleotide vaccines, and in particular the present invention provides immunogenic compositions comprising a polynucleotide encoding an antigen capable of eliciting an immune response and an adjuvant comprising an immunostimulatory quantity of a gemini surfactant, or a derivative thereof. | 02-24-2011 |
20110052643 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES - The invention relates to certain fused ring compounds, or pharmaceutically acceptable salts thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders. | 03-03-2011 |
20110052644 | COMPOSITION COMPRISING EXTRACT OF CINNAMOMUM CASSIA BARK FOR IMPROVING NORMAL FLORA AND ENHANCING IMMUNE RESPONSE - The present invention relates to a composition for improving intestinal flora and enhancing immune response containing | 03-03-2011 |
20110064771 | PLANT EXTRACTS AND USES THEREOF - Plant extracts obtainable by extracting various plant materials with an alkaline agent, methods for preparing such extracts, compositions comprising such extracts, and methods for using the extracts or compositions thereof are described. | 03-17-2011 |
20110070270 | IMMUNOSTIMULATING AGENT - An immunostimulating agent, which can stimulate immunity effectively, is described. The immunostimulating agent contains an active ingredient including a calcium receptor activator such as γ-Glu-X-Gly [wherein X represents an amino acid or a derivative thereof other than Cys], γ-Glu-Val-Y [wherein Y represents an amino acid or a derivative thereof], γ-Glu-Ala, γ-Glu-Gly, γ-Glu-Met, γ-Glu-Thr, γ-Glu-Val, γ-Glu-Orn, Asp-Gly, Cys-Gly, Cys-Met, Glu-Cys, Gly-Cys, Leu-Asp, γ-Glu-Met(O), γ-Glu-γ-Glu-Val, γ-Glu-Val-NH2, γ-Glu-Val-ol, γ-Glu-Ser, γ-Glu-Tau, γ-Glu-Cys(S-Me)(O), γ-Glu-Leu, γ-Glu-Ile, γ-Glu-t-Leu, γ-Glu-Cys(S-Me), a cation having a valency of 2 or more, protamine, polylysine, spermine, spermidine, putrescine, cinacalcet, a cinacalcet analogue compound, and a salt of any one of the aforementioned components. | 03-24-2011 |
20110104211 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF BREAST CANCER - Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly breast cancer. | 05-05-2011 |
20110117136 | DEHYDROEPIANDROSTERONE PRODUCTION PROMOTER AND USE THEREOF - A new orally administerable DHEA production promoter is provided. A composition containing an extract of at least one selected from the group consisting of plants of Rosaceae | 05-19-2011 |
20110195094 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY - The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound. | 08-11-2011 |
20110229525 | MODULATION OF CYTOKINE SIGNALING - Cell penetrating suppressor of cytokine signaling (CP-SOCS) molecules engineered to be resistant to intracellular degradation are discussed. Methods of treating diseases associated with cytokine signaling include one or more CP-SOCS degradation resistant molecules. | 09-22-2011 |
20110236429 | Small Cationic Antimicrobial Peptides - The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides. | 09-29-2011 |
20110250235 | PRODUCTION OF A SACCHARIDE COMPOSITION COMPRISING GLUCANS AND MANNANS BY ALKALINE AND ACID HYDROLYSIS OF YEAST CELLS - The present invention is directed to a method of production of an immunostimulatory composition having a saccharide fraction, the method including the steps of hydrolyses of yeast cells and recovering the soluble fraction. The saccharide fraction having composition thus obtained may be incorporated as a food or beverage component or be used as a pharmaceutical for treatment of specific conditions. | 10-13-2011 |
20110262485 | STING (STIMULATOR OF INTERFERON GENES), A REGULATOR OF INNATE IMMUNE RESPONSES - Novel molecules termed STING which include nucleic acids, polynucleotides, oligonucleotides, peptides, mutants, variants and active fragments thereof, modulate innate and adaptive immunity in a subject. STING compositions are useful for the treatment of an immune-related disorder, including treating and preventing infection by modulating immunity | 10-27-2011 |
20110287059 | HONEY ANALYSIS - A number of methods of analysing honey are described to determine the age of the honey, the presence of fortification with additives including methylglyoxal (MGO), the region from which the honey is derived, the plant species from which the honey is derived and whether the honey has been heated during processing. The various characteristics are determined based on the phenolic concentrations in the honey which have been found to provide very clear markers for the above characteristics. The methods of analysis described have many applications, particularly around quality assurance and ensuring that honeys are true to labeled specifications. | 11-24-2011 |
20110305729 | Scriptaid Isosteres and Their Use in Therapy - Compounds of the invention are of the formula (I); wherein: | 12-15-2011 |
20110305730 | MONO-AND DISACCHARIDE DERIVATIVES - The present invention relates to a novel family of monosaccharide derivatives and disaccharide derivatives and to a method of preparation thereof. A mono- and disaccharide derivatives according to the invention comprises at least one fatty acid ester and may further comprise one or more anionic groups and are useful for, inter alia, medical, pharmaceutical, cosmetic and food applications. | 12-15-2011 |
20110318388 | S1P Receptors Modulators and Their Use Thereof - The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as autoimmune response. | 12-29-2011 |
20120003270 | 6-SUBSTITUTED ISOFLAVONOID COMPOUNDS AND USES THEREOF - The present invention relates to 6-substituted isoflavonoid compounds and compositions comprising same. The invention further relates to the use of 6-substituted isoflavonoid compounds for the treatment of various diseases and conditions. | 01-05-2012 |
20120014998 | MODIFIED CHAPERONIN 10 - The present invention relates to isolated Chaperonin 10 polypeptides possessing immunomodulatory activity, but lacking, or substantially lacking, protein folding activity. | 01-19-2012 |
20120034270 | S1P Receptors Modulators - The invention relates to novel compounds that have S1P receptor modulating activity and, preferably, apoptotic activity and/or anti proliferative activity against cancer cells and other cell types. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with in-appropriate S1P receptor modulating activity or expression, for example, cancer. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as cancer. | 02-09-2012 |
20120039944 | WHEY AND THYMUS FUNCTION - The present invention generally relates to the field of nutrition and health. In particular, the present invention provides a composition that can be used to maintain or improve thymus health. One embodiment of the present invention is the use of whey or at least one protein fraction thereof for the preparation of a composition to maintain or improve thymus function. | 02-16-2012 |
20120039945 | Methods Of Immune Modulation - The present invention provides compounds and compositions thereof that modulate the immune system. | 02-16-2012 |
20120058148 | CERTAIN AMINOALKYL GLUCOSAMINIDE PHOSPHATE COMPOUNDS AND THEIR USE - Compounds that are adjuvants and immunoeffectors are described and claimed. The compounds augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages. Compositions and methods for using the compounds as adjuvants and immunoeffectors are also disclosed. | 03-08-2012 |
20120064121 | PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES - The invention relates to compounds that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders. | 03-15-2012 |
20120064122 | TREATMENT OF AUTOIMMUNE INFLAMMATION USING MIR-155 - The present disclosure relates to the finding that microRNA-155 plays a role in the development and activity of CD4+ T cells. CD4+ T cell development and function, particularly T | 03-15-2012 |
20120070463 | METHOD OF BIOTECHNOLOGICAL PRODUCTION FO BOVINE HEMODERIVATIVE AND USE OF BOVINE HEMODERIVATIVE - The method of biotechnological production of bovine hemoderivative is presented in the following overview providing a summary of individual technological operations in time sequence (Flow-Sheet). | 03-22-2012 |
20120076828 | KANAMYCIN ANTISENSE NUCLEIC ACID FOR THE TREATMENT OF CANCER - The invention relates to a nucleic acid comprising a sequence complementary to a fragment of the sequence coding for the kanamycin resistance protein. This nucleic acid is useful as a DNA vaccine adjuvant, and can be used e.g. for treating cancer, for example in combination with a non-immunosuppressive inducer of tumor cell apoptosis such as all-trans retinoic acid (ATRA). | 03-29-2012 |
20120082700 | COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS - Embodiments of the invention are directed to methods of treating, inhibiting or attenuating a microbial infection in an individual who has or is at risk for developing such an infection, comprising the step of administering an effective amount of a TLR9 agonist and a TLR 2/6 agonist to the individual. | 04-05-2012 |
20120082701 | POLARIZED SCORPION VENOM SOLUTION AND A METHOD FOR MAKING POLARIZED SCORPION VENOM SOLUTION - The present invention discloses a polarized dilute blue scorpion venom solution and a method for administering dilute scorpion venom solution. The polarized dilute scorpion venom solution provides treatment to various diseases and conditions such as relieving pain, improving immune-system responses, treating cancer, preventing cancer, improving quality of sleep, reducing inflammation, and minimizing negative biological response to chemotherapy and radiation treatment | 04-05-2012 |
20120082702 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS - Disclosed are nicotinamide compounds of Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. Also disclosed are methods of using such compounds in the treatment of at least one Btk associated condition, such as, for example, inflammatory disease, and pharmaceutical compositions comprising such compounds. | 04-05-2012 |
20120082703 | PHARMACEUTICAL COMPOSITION AND USE OF THE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT, PROPHYLAXIS OR PREVENTION OF NEOPLASTIC DISEASES IN HUMANS AND ANIMALS - The present invention relates to pharmaceutical compositions comprising polyfunctional metal phenolates that have biological applications as an anticancer adjuvant, cytoprotective antimetastatic agents and antimutagenic agents when associated with chemotherapy drugs. | 04-05-2012 |
20120087947 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING DERMATITIS - The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, dermatitis. | 04-12-2012 |
20120093873 | Molecular Interactions in Hematopoietic Cells - The invention provides reagents and methods for inhibiting or enhancing interactions between proteins in hematopoietic cells and other cells involved in the mediation of an immune response. Reagents and methods provided are useful for treatment of a variety of diseases and conditions mediated by immune system cells. | 04-19-2012 |
20120093874 | METHOD FOR SCREENING FOR DIET PROVIDING PRODUCTION OF MILK HAVING IMMUNOREGULATORY ACTION - A method for screening for a foodstuff providing production of milk having an immunoregulatory action, a novel foodstuff having an immunoregulatory action, and a method for producing it are provided. A diet or substance that increases or decreases an amount of microRNA present in milk of a mammal is identified by using correlation of microRNA profiles in the milk and a diet ingested by the mammal or a substance contained in the diet as an index to screen for a diet or a substance providing production of breast milk having an immunoregulatory action. | 04-19-2012 |
20120114700 | LAT ADAPTER MOLECULE FOR ENHANCED T-CELL SIGNALING AND METHOD OF USE - LAT (Linker for Activation of T-cells) is a protein involved in signaling through the T-cell receptor (TCR). The invention provides a LAT protein including mutations at ubiquitylation sites that result in an increase in stability of LAT in stimulated and unstimulated cells, and enhanced signaling through the TCR. The invention further provides use for a LAT protein including mutations at ubiquitylation sites for therapeutic and laboratory methods. | 05-10-2012 |
20120121650 | Chimeric Virus Vaccines - The present invention provides novel self-replicating and self-propagating chimeric viral vectors and chimeric virus particles comprising a modified genome of a carrier RNA virus packaged within structural proteins of a second virus. Also provided are pharmaceutical formulations comprising the chimeric viral vectors and virus particles and methods of inducing an immune response by administration of the chimeric viral vectors and virus particles or nucleic acids (e.g., DNA and/or RNA) encoding the same to the subject. | 05-17-2012 |
20120121651 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF - Pyrazolopyridin-4-amines, pyrazoloquinolin-4-amines, pyrazolonaphthyridin-4-amines, 6,7,8,9-tetrahydropyrazoloquinolin-4-amines, and prodrugs thereof, pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed. | 05-17-2012 |
20120128725 | DETECTION/MEASUREMENT OF MALARIA INFECTION DISEASE UTILIZING NATURAL IMMUNITY BY HEMOZOIN INDUCTION, SCREENING OF PREVENTATIVE OR THERAPEUTIC MEDICINE FOR MALARIA INFECTION DISEASE, AND REGULATION OF NATURAL IMMUNITY INDUCTION - The instant invention is to provide a method for detecting and measuring malaria infection utilizing the induction by hemozoin (HZ); a method for screening a vaccine for malaria infection and a preventative or therapeutic agent for malaria infection using the method for detecting and measuring; and a means for regulating the induction of innate immunity using the HZ, synthetic HZ, or derivatives thereof as an adjuvant or immunostimulant. Malaria infection is detected and measured of by detecting and measuring HZ-induced, TLR9-mediated, and MyD88-dependent innate immune activity. The detection and measurement of malaria infection can be used to diagnose malaria infection. The method for detecting and measuring is also used for screening a vaccine for malaria infection and a preventative or therapeutic agent for malaria infection. Further, HZ, synthetic HZ, or derivatives thereof are used as an adjuvant or immunostimulant to regulate HZ-induced innate immune induction. | 05-24-2012 |
20120135041 | IMMUNOSUPPRESSOR BASED ON THE BLOCKAGE OF TCR-NCK INTERACTION - The present invention relates to a compound of structural formula (I) and its derivatives for use as medicinal drugs. They are preferably immunosuppressive agents, with mechanism of action based on the blockage of TCR-Nck interaction. | 05-31-2012 |
20120135042 | Methods Using Immunomodulatory Compounds For Treatment of Certain Leukemias - Methods of treating, preventing or managing leukemias are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention. The invention further relates to methods of treatment using an immunomodulatory compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods of the invention are also disclosed. | 05-31-2012 |
20120135043 | IMMUNOMODULATORY PROPERTIES OF MULTIPOTENT ADULT PROGENITOR CELLS AND USES THEREOF - Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described. | 05-31-2012 |
20120141538 | MODULATORS OF THE CX3CRI RECEPTOR AND THERAPEUTIC USES THEREOF - The present invention concerns modulators of the CX3CR1 receptor. More specifically, antagonists and agonists of the CX3CR1 receptor have been identified. These antagonists and agonists can be used for treating an inflammatory disorder, an autoimmune disorder, a cardiovascular disease, a neurodegenerative disease, a graft versus host disease, a behavioral disorder, a cicatrisation disorder, a viral infection, cancer or pain. They may also be used as an adjuvant in a vaccine composition. | 06-07-2012 |
20120141539 | METHODS FOR MODULATING TOLL-LIKE RECEPTOR MEDIATED ACTIVATION OF CELLS OF THE INNATE SYSTEM BY MODULATING XBP-1 ACTIVITY - The invention provides methods and compositions for modulating the activity of XBP-I protein, or a protein in a signal transduction pathway involving XBP-I to modulate the TLR-mediated activation of cells of the innate immune system. Enhancing the TLR-mediated activation of cells of the innate immune system enhance inflammatory responses. The present invention also pertains to methods for identifying compounds that modulate Toll-like receptor-mediated signaling. | 06-07-2012 |
20120141540 | Drug Delivery System - Red blood cells can be used as effective drug delivery systems when they contain proteins that do not readily diffuse out and which form affinity complexes with the desired drug. | 06-07-2012 |
20120141541 | SYNERGISTIC MIXTURE OF BETA-GALACTO-OLIGOSACCHARIDES WITH BETA-1,3 AND BETA-1,4/1,6 LINKAGES - The present invention relates to a nutritional composition comprising at least two different beta-galacto-oligosaccharides (BGOS) A and B wherein the majority of linkages between two galactose residues in BGOS A are beta 1,4 and/or beta 1,6, and the majority of linkages between two galactose residues in BGOS B are beta 1,3. Such mixtures show superior effects on the immune system and are particularly suitable for infant nutrition. | 06-07-2012 |
20120156247 | BIOCOMPOSITION STIMULANT OF THE IMMUNE SYSTEM, ANTI-TUMOUR AND ANTI-HIV - Provided is a herbal composition of plants obtained from non-domestic wild sources by means of meristems and the extracts thereof obtained using improved processes, in which the extracts and the active principles thereof generate a synergism demonstrating anti-inflammatory, antiviral nutritional supplement, immune system simulating, prostatic health promoting and supporting properties for improving quality of life with a wide range of benefits in individuals with chronic terminal diseases. | 06-21-2012 |
20120156248 | AUGMENTATION OF TITER FOR VACCINATION IN ANIMALS - The disclosure relates to a composition added to animal feed used in combination with a vaccine to enhance the effectiveness of the vaccine. Amongst other effects, the composition raises the titer of antibodies to the vaccine. | 06-21-2012 |
20120171248 | COMPOUNDS AND METHODS FOR IMMUNOTHERAPY AND DIAGNOSIS OF TUBERCULOSIS - Compounds and methods for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more | 07-05-2012 |
20120177689 | GENERATION OF NOVEL BONE FORMING CELLS (MONOOSTEOPHILS) FROM LL-37 TREATED MONOCYTES - In one embodiment, a monocyte derived bone-forming cell population is provided. In one embodiment, the cell population comprises an isolated monocyte cell population treated with an effective dose of LL-37. In another embodiment, a method of producing a population of monocyte-derived bone-forming cells is provided. The method comprises obtaining a blood sample from a subject; isolating a population of monocytes from the blood sample; treating the isolated monocytes with an effective dose of LL-37; and culturing the LL-37 treated monocytes until they differentiate into the population of monocyte-derived bone-forming cells. In another embodiment, a method of treatment for a bone injury or bone disease is provided. The method comprises administering a therapeutically effective amount of a composition to a subject having the bone injury or disease, the composition comprising a population of monoosteophils. | 07-12-2012 |
20120177690 | USE OF RAPAMYCIN DERIVATIVES IN VASCULOPATHIES AND XENOTRANSPLANTATION - Use of a rapamycin derivative of formula I as defined in the claims for preventing or treating vasculopathies and manifestations of xenotransplantation. | 07-12-2012 |
20120177691 | FUCOSYLLACTOSE AS BREAST MILK IDENTICAL NON-DIGESTIBLE OLIGOSACCHARIDE WITH NEW FUNCTIONAL BENEFIT - The invention concerns nutritional compositions with fucosyllactose for use in stimulation of NK cells. The composition is suitable for infants. | 07-12-2012 |
20120183577 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES - The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides processes for preparing the compounds, pharmaceutically acceptable compositions comprising the compounds, and methods of using the compounds and compositions in the treatment of various disease, conditions, or disorders. | 07-19-2012 |
20120183578 | POLYETHYLENE GLYCOL-BASED DENDRONS - The instant invention relates to polyethylene glycol-based dendrons, otherwise known as PEGtide dendrons, compositions thereof and methods of use. | 07-19-2012 |
20120183579 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES - The invention relates to certain compounds, or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders. | 07-19-2012 |
20120195929 | COMPOUNDS THAT MODULATE AUTOIMMUNITY AND METHODS OF USING THE SAME - The invention provides methods of preventing, treating or ameliorating autoimmune diseases such as diabetes by modulating the binding of MHC class II molecules to antigenic peptides or fragments of antigenic peptides of the autoimmune disease by the administration of small organic compounds. The invention also provides pharmaceutical compositions comprising the therapeutically effective small organic compounds and methods of using the same. | 08-02-2012 |
20120195930 | NOVEL PYRIDINE DERIVATIVES - The invention relates to novel pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents. | 08-02-2012 |
20120207789 | TOPICAL CORNEAL ANALGESIA USING NEUROTENSIN RECEPTOR AGONISTS AND SYNERGISTIC NEUROTENSIN COMBINATIONS WITHOUT DELAYING WOUND HEALING - Ocular analgesics for topical administration are described. The topical ocular analgesic includes a neo-tryptophan-containing neurotensin analog. The topical ocular analgesic may alternatively include a buffered salt solution, a local anesthetic solution, a tissue penetrating agent, and/or an opiate. The neo-tryptophan-containing neurotensin analog may be present in a dose of about 0.0005 to about 1.2 mg. | 08-16-2012 |
20120207790 | IMMUNOSUPPRESSING AGENT COMPRISING MESENCHYMAL STEM CELL DERIVED FROM ADIPOSE TISSUE, AND USE THEREOF - To provide an immunosuppressing agent having high therapeutic effect and uses thereof. The immunosuppressing agent includes adipose-derived mesenchymal stem cells obtained by low-serum culture. | 08-16-2012 |
20120213823 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES THEREOF AND USES THEREOF - There are provided various compounds and compositions comprising polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds and compositions can be useful as cancer chemopreventive agents. They can also be useful for enhancing solubility of various active agents and enhancing their bioavailability. | 08-23-2012 |
20120213824 | USE OF PUFAS FOR TREATING SKIN INFLAMMATION - The present invention provides a compound which is a polyunsaturated fatty acid (PUFA) derivative of formula (I), | 08-23-2012 |
20120219591 | USE OF VECTORS EXPRESSING INTRACELLULAR POLYNUCLEOTIDE BINDING PROTEINS AS ADJUVANTS - An object of the invention is to provide a vaccine adjuvant that is comprised of a vector capable of expressing a polynucleotide binding protein in excess of levels already present in cells. Expression of the polynucleotide binding protein initiates intracellular pathways that lead to expression of type 1 interferons. In concert with expression of type 1 interferons, other cytokines are expressed, and the immune response to vaccine antigens given with the adjuvant is enhanced. | 08-30-2012 |
20120219592 | Use of B-Aminoalcohols in the Treatment of Inflammatory Disorders and Pain - A compound for therapeutic use, of the formula | 08-30-2012 |
20120219593 | INDOLYLMALEIMIDE DERIVATIVES PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS - A compound of formula (I) | 08-30-2012 |
20120219594 | Benzimidazole-imidazole Derivatives - Inhibitors of HCV replication of formula I | 08-30-2012 |
20120225095 | PRODUCTION OF CARBOXYLIC ACID AND SALT CO-PRODUCTS - This invention provide processes for producing carboxylic acid product, along with useful salts. The carboxylic acid product that is produced according to this invention is preferably a C | 09-06-2012 |
20120225096 | IMMUNOMODULATION USING PLACENTAL STEM CELLS - The present invention provides methods of immunomodulation using placental stem cells and placental stem cell populations. The invention also provides methods of producing and selecting placental cells and cell populations on the basis of immunomodulation, and compositions comprising such cells and cell populations. | 09-06-2012 |
20120225097 | PIPERAZINECARBOXAMIDE DERIVATIVE USEFUL AS A MODULATOR OF FATTY ACID AMIDE HYDROLASE (FAAH) - N-Pyridin-3-yl-4-{3-[4-(trifluoromethyl)phenoxy]benzyl}piperazine-1-carboxamide is described, which is useful as a FAAH inhibitor. N-Pyridin-3-yl-4-{3-[4-(trifluoromethyl)phenoxy]benzyl}piperazine-1-carboxamide may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). A method of synthesizing N-pyridin-3-yl-4-{3-[4-(trifluoromethyl)phenoxy]benzyl}piperazine-1-carboxamide is also disclosed. | 09-06-2012 |
20120237550 | Maintaining Antibody-Binding Activity Of Immunosuppressant Drug Conjugates - Methods and reagents are disclosed for maintaining the antibody-binding activity of a conjugate of an immunosuppressant drug and a conjugative moiety. The method comprises combining with the conjugate an effective amount of a chelating agent. Compositions include in an aqueous medium (i) a conjugate of an immunosuppressant drug and a conjugative moiety and (ii) a chelating agent in an amount effective to maintain an antibody-binding activity of the conjugate of the immunosuppressant drug and the conjugative moiety. The compositions may be employed in assays for the determination of analytes that include immunosuppressant drug analytes and antibodies for an immunosuppressant drug. | 09-20-2012 |
20120237551 | IMMUNE RESPONSE MODIFIER FORMULATIONS CONTAINING OLEIC ACID AND METHODS - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 09-20-2012 |
20120237552 | Peptoid Agonists of Nerve Growth Factor and Their Use as Medicaments - Neurotrophin binding to its specific receptors Trk A and p75 leads to the activation of multiple signalling cascades, culminating in neuroprotective and regenerative effects, including neuronal survival and neurite outgrowth. Neurotrophic factors have been used for the treatment of several neurodegenerative diseases. However, their use is limited by their inability to cross the blood-brain barrier, their short half life and their side effects. Small molecule neurotrophin mimetics may be beneficial in treating a number of neurodegenerative disorders. The present invention shows the capacity of nerve growth factor agonist molecules of Formulae I-IV, as defined in the specification, to induce differentiation in PC 12 cells, promote survival in RN22 cells and activate Trk A, IkBa and SAPK/JNK phosphorylation to various extents in both cell lines. In addition these molecules were able to ameliorate acute experimental autoimmune encephalomyelitis (EAE), a multiple sclerosis (MS) animal model, inhibiting brain inflammation and reducing brain damage. We also observed suppression in the production of pro-inflammatory genes like the inducible nitric oxide synthase. These small molecules with NGF agonist activity may be beneficial for MS and other neurodegenerative diseases due to its neuroprotective and immunomodulatory properties. | 09-20-2012 |
20120237553 | Process to Obtain a Homeopathic Medicament and Use Thereof - The present invention concerns a process to obtain a biological response modifier (BRM), particularly a medicament, as well as the medicament thus obtained and its use from highly diluted associations of vegetable, mineral and animal extracts, aiming to make use of its medicinal characteristics, internally and externally, in treatment, prevention, control and elimination of diseases, therapeutic and aesthetic finalities, in human beings. | 09-20-2012 |
20120251581 | Novel Compound and Methods for its Production - There is provided inter alia a compound of formula (I): | 10-04-2012 |
20120251582 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF - There are provided various compounds and compositions comprising polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds and compositions can be useful as cancer chemopreventive agents. They can also be useful for enhancing solubility of various active agents and enhancing their bioavailability. | 10-04-2012 |
20120258141 | Methods Of Immune Modulation - The present invention provides compounds and compositions thereof that modulate the immune system. | 10-11-2012 |
20120258142 | GLYCOLIPIDS AND ANALOGUES THEREOF AS ANTIGENS FOR NKT CELLS - This invention relates to immunogenic compounds which serve as ligands for NKT (natural killer T) cells and to methods of use thereof in modulating immune responses. | 10-11-2012 |
20120258143 | PHARMACEUTICAL FORMULATION AND PROCESS COMPRISING A SOLID DISPERSION OF MACROLIDE (TACROLIMUS) - The present invention relates to a pharmaceutical formulation and process for preparing the same comprising an oral dosage formulation, such as a capsule formulation, of a macrolide compound, such as tacrolimus, wherein the capsule formulation contains both a solid dispersion of the macrolide along with a non-dispersed form of the macrolide. The pharmaceutical formulation according to the invention is bioequivalent to the FDA approved product according to a bioavailability study conducted in humans. | 10-11-2012 |
20120258144 | SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE - The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating an immune-mediated disorder, such as, but not limited to, an autoimmune disease, by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide. Also disclosed are methods of suppressing an immune response in a subject by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide. | 10-11-2012 |
20120269861 | TREATMENT OF BREAST CANCER WITH IODONITROBENZAMIDES IN COMBINATION WITH ANTI-TUMOR AGENTS - In one aspect, the present invention provides a method of treating breast cancer that is negative for ER, PR, and HER2, comprising administering to a subject at least one iodonitrobenzamide. In another aspect, the present invention provides a method of treating breast cancer comprising administering to a subject at least one iodonitrobenzamide in combination with at least one anti-tumor agent. | 10-25-2012 |
20120269862 | OPHTHALMIC COMPOSITION WITH A VISCOSITY ENHANCEMENT SYSTEM HAVING TWO DIFFERENT VISCOSITY ENHANCING AGENTS - An ophthalmic composition is disclosed having a viscosity enhancement system comprised of two different viscosity enhancing agents. The aqueous composition contains a first viscosity enhancing agent that provides enhanced viscosity upon dispensing of the composition to the eye and a second viscosity agent that increases viscosity (e.g., gels or partially gels) after dispensing of the composition to the eye to provide extended viscosity enhancement of the composition. | 10-25-2012 |
20120269863 | METHODS AND COMPOSITIONS FOR REGULATING LYMPHOCYTE ACTIVITY - The present application is directed to the discovery that hedgehog gene products, and signal transduction pathways involving hedgehog, are involved in maturation of T lymphocytes. The invention provides a method to promote T lymphocyte development using low dose Hedghog, and a method to inhibit T lymphocyte development using high dose Hedgehog. Certain aspects of the invention are directed to preparations of hedgehog polypeptides, agonists, antagonists, or other molecules which regulate patched or smoothened signalling, and their uses as immunomodulatory agents. | 10-25-2012 |
20120269864 | Arginine Derivatives with NP-I Antagonistic Activity - The present invention is a compound of formula (I) or formula (II) which are suitable as NP-1 antagonists. | 10-25-2012 |
20120269865 | NUTRITIONAL COMPOSITION FOR PROMOTING GUT MICROBIOTA BALANCE AND HEALTH - The present disclosure relates to nutritional compositions comprising a fructo-oligosaccharide (FOS) in an amount of 35 to 44% by weight; a polysaccharide that is not a partially hydrolyzed guar gum such as, for example, an arabinogalactan in an amount of 50% to 38% by weight; and inulin in an amount of 12% to 24% by weight. The FOS and the polysaccharide may be present in a weight ratio of about 1:1. More specifically, the FOS and inulin may be present in a weight ratio of about 7:3. Also provided are methods of promoting gut microbiota balance and health. The methods include administering an effective amount of the nutritional composition to patients in need of same. | 10-25-2012 |
20120282296 | METHODS FOR IMPROVING THE DESIGN, BIOAVAILABILITY, AND EFFICACY OF DIRECTED SEQUENCE POLYMER COMPOSITIONS VIA SERUM PROTEIN-BASED DETECTION OF DIRECTED SEQUENCE POLYMER COMPOSITIONS - There exist in the art methods of detecting simple peptides. However, methods to determine the effective plasma concentration of directed sequence polymers (DSPs), are complicated because DSPs are complex mixtures of peptides, as opposed to individual peptides with a defined amino acid sequence. This application provides improved methods of detecting and assessing DSP compositions, methods for the detection and quantitation of DSP compositions, means to determine and enrich a subset of peptides in a DSP composition based on the subset's interactions with certain capture polypeptides, and methods for administering DSP compositions to a subject in need thereof, wherein the dosage regimen and quantity may be determined or evaluated based on the above-mentioned methods for detection and quantitation. | 11-08-2012 |
20120288528 | MONO-AND DISACCHARIDE DERIVATIVES - The present invention relates to a novel family of monosaccharide derivatives and disaccharide derivatives and to a method of preparation thereof. A mono- and disaccharide derivatives according to the invention comprises at least one fatty acid ester and may further comprise one or more anionic groups and are useful for, inter alia, medical, pharmaceutical, cosmetic and food applications. | 11-15-2012 |
20120294895 | PROTEIN A COMPOSITIONS AND METHODS OF USE - Methods and compositions for modulating an immune response in a subject are provided. Methods include administering to the subject a composition comprising an effective amount of a lymphocyte differentiation factor, e.g., protein A (PA), sufficient to modulate the immune response. Compositions include a lymphocyte differentiation factor, e.g., protein A (PA), in an amount less than 1 μg. | 11-22-2012 |
20120294896 | Methods and Compositions for Poxvirus A35R Protein - The present invention provides methods and compositions for modulating an immune response in a subject, comprising administering to the subject an effective amount of an A35R protein or active fragment thereof of vaccinia virus or other poxvirus. | 11-22-2012 |
20120301505 | Immunostimulating Agent and Method for Production Thereof - The object is to provide: a safe immunomodulating agent which can be used as a pharmaceutical or a food material; a method for production of the immunomodulating agent; and a novel application of a coffee extract residue. Disclosed is an immunomodulating agent comprising a coffee extract as an active ingredient. Preferably, the coffee extract is an extract containing arabinogalactan. The immunomodulating effect of the immunomodulating agent relies on the promotion of the proliferation of an immunocompetent cell such as a macrophage. The immunocompetent cell is preferably any one selected from a macrophage like strain RAW264 or J774.1, a murine splenocyte, a murine peritoneal macrophage and a murine dendrocyte. A composition containing the immunomodulating agent can be used as a composition such as a pharmaceutical composition, a food composition and a cosmetic composition. | 11-29-2012 |
20120308606 | BICYCLIC DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS - Bicyclic derivatives useful as ion channel antagonists are disclosed herein. The compositions thereof are useful for treating or relieving pain-related conditions. | 12-06-2012 |
20120308607 | PRODUCTION AND USE OF HUMAN CD124- AND CD-116-POSITIVE TUMOR CELL LINES IN THE PRODUCTION OF ALLOGENIC OR SEMI-ALLOGENIC IMMUNOTHERAPY AGENTS - The invention is related to the production and use of CD124+ and CD116+ cell lines for the production of effective dendritic cells (DC) using stimulatory molecules, their use in the production of allogenic or semi-allogenic immunotherapeutic agents and the use thereof in the treatment or prophylaxis of immune diseases. Furthermore, the invention is related to the use of CD124+ and CD116+ tumor cell lines, preferably also being CD34+, as model and yeast systems for testing the DC biology and for testing substances having an impact on the immune system and on the conditioning thereof. | 12-06-2012 |
20120308608 | INTERFERON-INDUCING COMPOUNDS AND USES THEREOF - Provided herein are Compounds that induce interferon production and methods for identifying such Compounds. Also provided herein are compositions comprising such Compounds and methods of using such Compounds to treat interferon-sensitive diseases such as viral infections, cancer, and multiple sclerosis. | 12-06-2012 |
20120308609 | 6-AMINO-2--9-[5-(1-PIPERIDINYL)-7,9-DIHYDRO-8H-PURIN-8-ONE MALEATE - The present invention relates to a compound which is 6-amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one: | 12-06-2012 |
20120315298 | LOCAL TREATMENT OF NEUROFIBROMAS - A method for treating a neurofibroma, e.g. dermal neurofibroma, a subdermal neurofibroma, or a superficial plexiform neurofibroma, in a subject in need of such treatment is disclosed. The method comprises locally applying a composition to a neurofibroma either topically or intralesionally. This method does not encompass systemic administration of the composition to the subject to have an effect on the neurofibromas. Compositions useful for such treatments and methods of preparing the compositions are disclosed. | 12-13-2012 |
20120315299 | PHARMACEUTICAL COMPOSITION FOR INTRACELLULAR ACIDIFICATION WITH CIS-UROCANIC ACID - A pharmaceutically acceptable agent able to acidify the cell cytoplasm, for the manufacture of a pharmaceutical composition useful for causing immunosuppression in a person or animal, where an effective amount of the agent is administered in an essentially non-dissociated form to the person or animal, and where the agent is admixed with a carrier to adjust the pH of the composition to the pH range 6.1 to 7.0. A pharmaceutical composition is also disclosed. | 12-13-2012 |
20120321666 | T CELL THERAPY FOR B CELL LYMPHOMA - Disclosed are methods and compositions for improving anti-tumor response and survivability in patients with cancer, such as non-Hodgkin lymphoma. In certain aspects, methods are provided for infusing lymphoma patients with T cells that are propagated ex vivo. Also provided are methods and compositions for propagating canine T cells ex vivo for infusion into cancer patients. | 12-20-2012 |
20120321667 | T CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONS - The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same. | 12-20-2012 |
20120328661 | COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY - The present invention relates to novel 2-oxo-2H-chromene-3-carboxamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 12-27-2012 |
20120328662 | COMPOSITION FOR INHIBITING TUMOR CELL PROLIFERATION - This invention pertains to cancer immunotherapy, by providing a proinflammatory dendritic cell (DC), which has been stimulated to maturation ex vivo by specific treatment, a method for such treatment and a composition comprising the proinflammatory DC. The DC may be used as a cell based immunotherapy for inhibiting tumor cell proliferation. | 12-27-2012 |
20120328663 | Composition of Beta-Glucan and Ashwagandha - Compositions including combinations of β-glucan and | 12-27-2012 |
20120328664 | LIQUID FORMULATIONS - Disclosed is a concentrate for dilution comprising a S1P receptor agonist or a pharmaceutically acceptable salt thereof, propylene glycol and optionally glycerin. This formulation is adapted for patients in a difficult condition to swallow. | 12-27-2012 |
20130004540 | BIFIDOBACTERIUM STRAIN - strain AH121A is significantly immunomodulatory following oral consumption. The strain is useful as an immunomodulatory biotherapeutic agent. | 01-03-2013 |
20130017223 | METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS - A lipid particle can include a plurality of cationic lipids, such as a first cationic lipid and a second cationic lipid. The first cationic lipid can be selected on the basis of a first property and the second cationic can be selected on the basis of a second property. The first and second properties are complementary. The attributes of the lipid particle can reflect the selected properties of the cationic lipids, and the complementary nature of those properties. | 01-17-2013 |
20130017224 | Nucleic Acid Molecules Encoding Rantes, and Compositions Comprising and Methods of Using the Same - Nucleic acid molecules comprising a nucleotide sequence encoding RANTES and fragments and variants thereof are disclosed. Additionally, nucleic acid molecules and compositions comprising the nucleotide sequence encoding RANTES and fragments and variants thereof in combination with nucleic acid sequences encoding immunogens are provided. Recombinant viral vectors comprising the nucleotide sequence encoding RANTES and fragments and variants thereof with or without a nucleic acid sequence encoding immunogens are also provided as are live attenuated pathogens comprising a nucleotide sequence encoding RANTES and fragments and variants thereof. Methods of modulating immune responses and of inducing an immune response against an immunogen are also disclosed. | 01-17-2013 |
20130017225 | NATURAL PLANT PRODUCTS FOR CONTROL OF CANCER METASTASIS - The invention provides compositions comprising soluble extracts or isolated polypeptides from the edible roots of the plant | 01-17-2013 |
20130017226 | TNF-A and TWEAK Dual Antagonist for the Prophylaxis and Treatment of Autoimmune DiseasesAANM Park; Young WooAACI DaejeonAACO KRAAGP Park; Young Woo Daejeon KRAANM Jo; Ki WonAACI Gyeonggi-doAACO KRAAGP Jo; Ki Won Gyeonggi-do KRAANM Yoo; Srok HoAACI DaejeonAACO KRAAGP Yoo; Srok Ho Daejeon KRAANM Yu; JungAACI DaejeonAACO KRAAGP Yu; Jung Daejeon KRAANM Kim; Dong JiAACI DaejeonAACO KRAAGP Kim; Dong Ji Daejeon KRAANM Yoon; Sun-HaAACI DaejeonAACO KRAAGP Yoon; Sun-Ha Daejeon KRAANM Song; Eun JungAACI DaejeonAACO KRAAGP Song; Eun Jung Daejeon KRAANM Lee; Eun KyungAACI Gyeonggi-doAACO KRAAGP Lee; Eun Kyung Gyeonggi-do KRAANM Oh; Jin MiAACI Gyeonggi-doAACO KRAAGP Oh; Jin Mi Gyeonggi-do KRAANM Cho; Kyu WonAACI SeoulAACO KRAAGP Cho; Kyu Won Seoul KRAANM Cho; Mi LaAACI SeoulAACO KRAAGP Cho; Mi La Seoul KRAANM Kim; Ho YounAACI SeoulAACO KRAAGP Kim; Ho Youn Seoul KRAANM Park; Mi KyungAACI Gyeonggi-doAACO KRAAGP Park; Mi Kyung Gyeonggi-do KRAANM Oh; Hye JwaAACI SeoulAACO KRAAGP Oh; Hye Jwa Seoul KRAANM Park; Jin SilAACI SeoulAACO KRAAGP Park; Jin Sil Seoul KRAANM Woo; Yun JuAACI SeoulAACO KRAAGP Woo; Yun Ju Seoul KRAANM Byun; Jae KyeongAACI Chungcheongbuk-doAACO KRAAGP Byun; Jae Kyeong Chungcheongbuk-do KRAANM Ryu; Jun GeolAACI Gangwon-doAACO KRAAGP Ryu; Jun Geol Gangwon-do KR - The present invention relates to TNFR2-TWEAKR fusion protein, more precisely to TNFR2-TWEAKR fusion protein acting as a double-antagonist to TNF-α and TWEAK, known as major causes of autoimmune arthritis which is one of autoimmune diseases. When the composition comprising TNFR2-TWEAKR fusion protein was treated to Th17 cells, the secretion of the inflammatory cytokine IL-17 was reduced but the secretion of the anti-inflammatory cytokine IL-10 generated in Treg cells was increased. Such effect of TNFR2-TWEAKR fusion protein was far greater than that of a single protein such as TNFR2-Fc or TWEAK-Fc. The TNFR2-TWEAKR fusion protein of the present invention has not only excellent treatment effect on arthritis in CIA mouse model not also excellent treatment effect on autoimmune rheumatoid arthritis by increasing the expression of Treg, the immune suppressive cells. Therefore, the TNFR2-TWEAKR fusion protein of the present invention can be effectively used as an active ingredient for the composition for the prevention and treatment of autoimmune disease. | 01-17-2013 |
20130022641 | Anti-Tumor Agent and Immunostimulating Agent - To provide a pharmaceutical composition comprising a ceramide-related substance having little adverse side effects as an active ingredient by using a raw material that is highly safe to a human body and is inexpensive. A pharmaceutical composition comprising at least one sphingoglycolipid derivative that is produced from a beer waste and is represented by the formula below as an active ingredient: wherein R3 represents H or OH; R4 is as defined by (a) or (b) (a) when R3 is H, R4 represents (CH2)13CH3 or (CH2)6CH═CHCH2CH═CH(CH2)4CH3; and (b) when R3 is OH, R4 represents (CH2)yCH3 (where Y represents an integer of 13 to 21) or (CH2)Z1CH═CH(CH2)Z2CH3 (where Z1 and Z2 independently represent 0 or a natural number, provided that Z1+Z2=19). | 01-24-2013 |
20130022642 | Dual Antagonist for TNF-A and IL-21 for Preventing and Treating Autoimmune Diseases - The present invention relates to TNFR2-IL21R fusion protein acting as a double-antagonist to TNF-alpha (α) and IL-21. The composition containing the double antagonist to TNF-α and Il-21 (TNFR2-IL21R fusion protein), known as major causes of autoimmune rheumatoid arthritis, one of autoimmune diseases, can reduce the secretion of inflammatory cytokine, increase the secretion of anti-inflammatory cytokine, and suppress the differentiation of osteoclasts better than single proteins such as TNFR2-Fc and IL21R-Fc. The TNFR2-IL21R fusion protein of the present invention has not only excellent treatment effect on arthritis in CIA mouse model not also excellent treatment effect on autoimmune rheumatoid arthritis by increasing the expression of Treg, the immune suppressive cells. Therefore, the TNFR2-IL21R fusion protein of the present invention can be effectively used as an active ingredient for the composition for the prevention and treatment of autoimmune disease. | 01-24-2013 |
20130039948 | Inhibition of TCR Signaling with Peptide Variants - The present invention provides compositions comprising peptides derived from amino acid sequences (or from combinations thereof) of fusion and other protein regions of various viruses, including but not limited to, severe acute respiratory syndrome coronavirus, herpesvirus saimiri, human herpesvirus 6, Lassa virus, lymphocytic choriomeningitis virus, Mopeia virus, Tacaribe virus, Friend murine leukemia virus; human T lymphotropic virus type 1; herpesvirus ateles; Marburg virus; Sudan Ebola virus; Zaire Ebola virus, and comprising L- and/or D-amino acids and combinations thereof, which affect T cells by acting on the T cell antigen receptor (TCR). More specifically, the peptides act on the TCRαβ-CD3δε-CD3γε-ζζ signaling complex. Yet more specifically, the peptides act on the TCRα/CD3δε/ζζ signaling module of TCR. The present invention further relates to the prevention and therapy of various T cell-related disease states involving the use of these compositions. Specifically, the compositions are useful in the treatment and/or prevention of a disease or condition where T cells are involved or recruited. The compositions of the present invention also are useful in the production of medical devices comprising peptide matrices (for example, medical implants and implantable devices). | 02-14-2013 |
20130045236 | DIAGNOSTIC AND THERAPEUTIC USES OF SOLUBLE FC-EPSILON RECEPTOR I FOR IGE-MEDIATED DISORDERS - The present disclosure is based in part on the finding that sFcεRI is a novel biomarker for IgE-mediated disorders. Methods for diagnosing, treating and/or monitoring IgE-mediated disorders are also described. The disclosure further provides assays to detect sFcεRI in a sample. | 02-21-2013 |
20130058980 | SMALL MOLECULE INHIBITORS OF PROTEIN KINASES - Compounds that modulate, for example, that inhibit, syk kinase, and, optionally other kinases. The compounds can be used to treat a variety of disorders, including inflammatory disorders and autoimmune disorders. | 03-07-2013 |
20130064858 | POLYSACCHARIDE SUITABLE TO MODULATE IMMUNE RESPONSE - Objective of the present invention is to provide polysaccharides which modulate immune response, and which can be used as ingredients in edible products or pharmaceutical compositions. The present invention provides such polysaccharides obtained from the species | 03-14-2013 |
20130071435 | NOVEL HERBAL FORMULATION FOR THE MODULATION OF IMMUNE SYSTEM OF HIV INFECTED PATIENTS AND A PROCESS OF PREPARATION THEREOF - An herbal formulation for the modulation of immune system of HIV infected patients and a process of preparation thereof are provided. The process includes (i) preparing a hydromethanolic extract of at least one plant selected from Hippophae rhamnoides, | 03-21-2013 |
20130071436 | TREATMENT OF T-CELL MEDIATED DISEASES - The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions. | 03-21-2013 |
20130071437 | IMMUNOLOGICAL FUNCTION ENHANCING AGENT - An agent, as an active ingredient thereof, includes activated lymphocytes derived from a tissue of an animal, in which antibodies and immunocytes do not pass from a mother to a fetus across the placenta, and which is used to enhance the immunological functions of another animal of the same species as the animal from which the lymphocytes are derived. A method for producing an agent for enhancing immunological functions of another animal, in which lymphocytes isolated from an animal are grown and activated to produce activated lymphocytes. | 03-21-2013 |
20130078280 | CYCLOSPORINE ANALOGUE MIXTURES AND THEIR USE AS IMMUNOMODULATING AGENTS - The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISA | 03-28-2013 |
20130095138 | Method and Apparatus for Producing a Stabilized Antimicrobial Non-toxic Electrolyzed Saline Solution Exhibiting Potential as a Therapeutic - An improved method and apparatus for producing a stable, non-toxic, antimicrobial electrolyzed saline solution with a broad range of anti-infective and therapeutic applications. The resulting electrolyzed saline solution exhibits a marked lack of toxicity upon intravenous, aspired, oral or topical application in mammals for therapeutic applications providing a broad platform, including topical disinfection, antimicrobial application, wound treatment, oxidative stress reduction and enhancement of immune function to better detect malfunctioning cells. | 04-18-2013 |
20130101627 | COMPOSITION WITH EXTRACTS FROM OLIVE LEAF, YARROW AND ROSEMARY FOR TREATING HUMAN DISEASES AND CONDITIONS - The present invention is a medical composition for treating a variety of human diseases and conditions. It comprises an effective amount of Olive Leaf extract, Yarrow extract and Rosemary extract as active components. Its inactive components include | 04-25-2013 |
20130122050 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE - Pharmaceutical compositions and methods are provided for treating diabetes and/or restoring β-cell mass and function in a mammal in need thereof. Type 1 diabetes mellitus (T1 DM) is an autoimmune disorder characterized by immune damage to pancreatic beta-cells. Lisofylline analogs (LSF analogs) are immunomodulators that reduce interlukin 12 signaling and reduce the onset of T1 DM in non-obese diabetic (NOD) mice. A combination therapy with both LSF analog (pretreatment) and INGAP provides protection from autoimmune destruction. The concomitant or combination of an LSF analog and INGAP after pre-treatment with an LSF analog is an effective therapy for a disease or condition resulting from the loss of pancreatic islet cells or insulin production in a mammal. | 05-16-2013 |
20130129785 | METHODS AND COMPOSITIONS FOR DELIVERY OF ACTIVE AGENTS - A lipid particle can include a cationic lipid. Synthesis of the cationic lipid can include a ylide-based reaction, such as a Wittig reaction or sulfur ylide reaction. In some cases, the synthesis can also include a Michael addition or a related addition reaction. | 05-23-2013 |
20130136770 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION - Provided herein are methods for modulating immune responses to a respiratory viral infection (e.g., influenza, rhinovirus, coronavirus, or paramyxovirus) in a subject, wherein the methods comprise administering to the subject a compound (e.g., a PDE4 modulator or an immunomodulatory compound), or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof. Also provided herein are methods for treating, preventing, ameliorating, and/or delaying the onset of one or more symptoms associated with or resulting from a respiratory viral infection (e.g., influenza, rhinovirus, coronavirus, or paramyxovirus) in a subject, wherein the methods comprise administering to the subject a compound (e.g., a PDE4 modulator or an immunomodulatory compound), or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof. | 05-30-2013 |
20130136771 | OLIGODEOXYNUCLEOTIDE AND ITS USE TO INDUCE AN IMMUNE RESPONSE - A substantially pure or isolated oligodeoxynucleotide of at least 10 nucleotides is disclosed, wherein the oligodeoxynucleotide comprised a sequence represented by either formula: | 05-30-2013 |
20130136772 | REGULATION OF IMMUNE RESPONSE BY COLOCYNTHIN AND/OR ITS DERIVATIVES - The present invention relates to a method of inhibiting pro-inflammatory and T-cell mediated cytokines, said method comprising step of administering to a subject in need thereof a therapeutically effective amount of colocynthin and/or its derivatives. The invention also relates to a method of inhibiting T-cell surface markers and to a method of regulating immune response by colocynthin and/or its derivatives. | 05-30-2013 |
20130142831 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES - The invention relates to compounds of formula (I): | 06-06-2013 |
20130142832 | NUCLEIC ACID/ POLYSACCHARIDE COMPLEX - An object of the present invention is to provide a highly stable nucleic acid-polysaccharide complex of an siRNA and schizophyllan. A nucleic acid-polysaccharide complex is formed by adding polydeoxyadenine in which at least part of the phosphodiester link portion is phosphorothioated to an siRNA and allowing the siRNA and schizophyllan to form a complex. | 06-06-2013 |
20130149341 | METHODS OF IMPROVING SKIN QUALITY - Methods of improving skin quality are disclosed. Generally, the methods include topically administering an IRM compound to a treatment area of skin for a period of time and in an amount effective for improving the quality of the skin. Suitable IRM compound compounds include agonists of one or more TLRs. | 06-13-2013 |
20130156814 | METHODS OF TREATMENT USING TLR7 AND/OR TLR9 INHIBITORS - The application relates to compositions and methods of regulating an immune response comprising inhibitors of TLR7 and/or TLR9, such as immunoregulatory polynucleotides and/or immunoregulatory compounds. The application also relates to compositions and methods for predicting and/or determining responsiveness of a disease to treatment comprising inhibitors of TLR7 and/or TLR9. | 06-20-2013 |
20130164333 | IMMUNE STIMULATORY OLIGORIBONUCLEOTIDE ANALOGS CONTAINING MODIFIED OLIGOPHOSPHATE MOIETIES - Immunostimulatory oligoribonucleotides (ORN) featuring 5′-triphosphates and various 5′-triphosphate analogs are provided. Also provided are physiologically acceptable salts of the immunostimulatory ORN and pharmaceutical compositions containing the immunostimulatory ORN of the invention. ORN of the invention are useful as adjuvants and can be combined with an antigen to promote an antigen-specific immune response. ORN of the invention are also particularly useful for promoting a Th1-type immune response. Also provided are methods of use of the compounds and pharmaceutical compositions of the invention to enhance an immune response in a subject, as well to treat a number of conditions including cancer, infection, allergy, and asthma, and to vaccinate a subject against an antigen. | 06-27-2013 |
20130171196 | Immunomodulatory Compounds for the Restoration of Vitamin D Sensitivity in Vitamin D Resistant Tumor Cells - Provided herein are methods of restoring vitamin D sensitivity in tumor cells that are vitamin D resistant. Also provided are methods of treating, preventing or managing cancer using an immunomodulatory compound in combination with a vitamin D agent. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods provided herein are also disclosed. | 07-04-2013 |
20130177596 | Endophytic Fungi from Pteromischum SP. Plant, Compounds and Methods of Use - The present disclosure relates to endophytic fungi from higher plants such as a | 07-11-2013 |
20130177597 | Mango seed herbal medication - An herbal composition for treatment of kidney nephrotic syndrome formed of a mixture of the herbs mango seed powder, | 07-11-2013 |
20130183347 | Somatic Transgene Immunization and Related Methods - The invention provides a method for stimulating an immune response by administering to a lymphoid tissue a nucleic acid molecule comprising an expression element operationally linked to a nucleic acid sequence encoding one or more heterologous epitopes. The heterologous epitope can be inserted into a complementarity-determining region of an immunoglobulin molecule. The invention also provides a nucleic acid molecule comprising a hematopoietic expression element operationally linked to a nucleic acid sequence encoding a heterologous polypeptide. The invention additionally provides a method of treating a condition by administering a nucleic acid molecule comprising a hematopoietic cell expression element operationally linked to a nucleic acid sequence encoding a heterologous polypeptide, wherein the nucleic acid molecule is targeted to a hematopoietic cell. | 07-18-2013 |
20130183348 | Inhibitor of HMGB Protein-Mediated Immune Response Activation, and Screening Method - Provided are an inhibitor of activation of an immune response mediated by an HMGB protein, the inhibitor containing at least one compound selected from the group consisting of a phosphorothioate oligonucleotide and a derivative thereof, and a method of screening for an inhibitor or enhancer of activation of an immune response mediated by an HMGB protein, the method including a mixing step of mixing an HMGB protein and a labeled nucleic acid in the presence and absence of a test substance; a quantifying step of quantifying the HMGB protein bound to the labeled nucleic acid; and a determination step of determining that the test substance is an inhibitor of activation of an immune response mediated by the HMGB protein when the amount of the HMGB protein bound to the labeled nucleic acid in the presence of the test substance is less than the amount of the HMGB protein bound to the labeled nucleic acid in the absence of the test substance and determining that the test substance is an enhancer of activation of an immune response mediated by the HMGB protein when the amount of the HMGB protein bound to the labeled nucleic acid in the presence of the test substance is higher than the amount of the HMGB protein bound to the labeled nucleic acid in the absence of the test substance. | 07-18-2013 |
20130189311 | ARRANGING INTERACTION AND BACK PRESSURE CHAMBERS FOR MICROFLUIDIZATION - An improved method for the manufacture of an oil-in-water emulsion comprises using a microfluidisation device whose interaction chamber comprises a plurality of Z-type channels upstream of a back pressure chamber. | 07-25-2013 |
20130195919 | INDUCED DENDRITIC CELL COMPOSITIONS AND USES THEREOF - The invention provides, for example, compositions comprising induced tolerogenic dendritic cells which are capable of suppressing an antigen specific T cell-mediated immune response, and to methods of making and using the same. The invention also provides compositions comprising induced immunogenic dendritic cells and methods of making and using them. | 08-01-2013 |
20130202646 | COMPOSITIONS AND METHODS FOR MODULATING AUTOPHAGY - In alternative embodiments, the invention provides cell-permeable recombinant or synthetic proteins to modulate autophagy, including a Tat-Atg5K130R (inhibitor of autophagy) and a Tat-Beclin 1 (stimulant or activator of autophagy), and nucleic acids expressing them and methods for making and using them, e.g., to treat conditions and disorders responsive to autophagy modulation (e.g., where autophagy is dysregulated), including neurodegeneration, cystic fibrosis, cancer, heart failure, diabetes, obesity, sarcopenia, aging, ischemia/reperfusion, inflammatory disorders including Crohns, ulcerative colitis, biliary cirrhosis, lysosomal storage diseases, infectious diseases associated with intracellular pathogens including viruses, bacteria, and parasites such as Trypanosomes and malaria. | 08-08-2013 |
20130202647 | Chloroplast Expression of Membrane Proteins - Disclosed herein are chloroplast transformation vectors constructed to enable expression and hyperaccumulation of membrane proteins in chloroplasts. Another embodiment relates to plants transformed with such vectors. Another embodiment relates to seeds and other plant tissues transformed with such vectors. Another embodiment relates to a method of increasing expression of membrane proteins in chloroplasts including transforming a plant cell with vectors described herein. | 08-08-2013 |
20130202648 | Immunoregulator Compounds - The invention relates to sphingosine derivative compounds, like D-erythro-sphingosine | 08-08-2013 |
20130202649 | ACTIVATION OF INNATE IMMUNITY FOR NUCLEAR REPROGRAMMING OF SOMATIC CELLS - The nuclear reprogramming of somatic cells with non-integrating factors is shown to be greatly accelerated by activation of innate immune responses in the somatic cell. Methods of activating innate immunity include activation of toll-like receptors, e.g. TLR3. Somatic cells with activated innate immune responses can be reprogrammed to induced pluripotent cells or to transdifferentiated cells. | 08-08-2013 |
20130202650 | TOPICAL COMPOSITION COMPRISING A COMBINATION OF AT LEAST TWO PENETRATION ENHANCING AGENTS - The present invention relates to a composition for improved transdermal drug delivery comprising a drug, a combination of at least two penetration enhancing agents, wherein at least on the of the penetration enhancing agents is selected from the group consisting of esters of saturated or unsaturated fatty acids and lower alcohols, and iso-form alcohols; wherein at least one of the penetration enhancing agents is selected from the group consisting of aliphatic diols and triols; and wherein the components are present in a non-aqueous solvent system. A preferred topical composition comprises the active substance imiquimod and the penetration enhancing agents isoproply myristate and propylene glycol. | 08-08-2013 |
20130202651 | COMPOSITE VACCINE ADJUVANT - The invention provides a composite vaccine adjuvant, which is comprised of sodium ferulate and zinc hydroxide in a mass ratio of 10:1˜50:1. When the composite vaccine adjuvant and vaccine used in combination, the humoral immunity response is enhanced effectively, the enhanced effects is similar with aluminum adjuvant, superior to single sodium ferulate adjuvant and single zinc hydroxide adjuvant. It is not only atoxic, safety, but also reliable in the range of immune dose. The composite vaccine adjuvant with easily obtained and commercially available raw materials, is low cost, stable performance and simple preparation technology, which can be used as an adjuvant of hepatitis B vaccine, gene-engineered vaccine, virus vaccine and so on. | 08-08-2013 |
20130202652 | METHODS AND COMPOSITIONS FOR DELIVERY OF ACTIVE AGENTS - A targeting lipid can have the formula (I) in which T4 is a targeting moiety. The targeting moiety can be chosen to favor the lipid being localized with a desired organ, tissue, cell, cell type or subtype, or organelle. The targeting moiety can include, for example, transferrin, anisamide, an RGD peptide, prostate specific membrane antigen (PSMA), fucose, an antibody, or an aptamer. | 08-08-2013 |
20130202653 | 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINOPROPIONIC ACID AMIDES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY - Compounds of Formulas 1 and 2 | 08-08-2013 |
20130209515 | ANTI-INFECTIVE AND IMMUNOMODULATORY COMPOUNDS - The present invention provides pharmaceutical compositions and methods that include the use of anti-infective compounds that potentiate the host-immune response or limit or prevent the expression or activity of individual virulence factors. In addition, the compositions have immunomodulatory activity, and therefore can be used to prime host defenses to prevent or limit bacterial, fungal, and viral viability. In the compositions and methods of the inventions, specific steps of the bacterial-, fungal-, or viral-host interaction are targeted to prevent pathogenesis (e.g., infection). Such an approach should prevent pathogenic organisms from acquiring resistance to the protective anti-infective compounds. | 08-15-2013 |
20130209516 | IMMUNOMODULATORY COMPOSITIONS - Isolated immunomodulatory (e.g. immunostimulatory) polyhydroxlated pyrrolizidine compounds having the formula (I), wherein R is selected from the group comprising hydrogen, straight or branched, unsubstituted or substituted, saturated or unsaturated acyl, alkyl (e.g. cycloalkyl), alkenyl, alkynyl and aryl groups, or a pharmaceutically acceptable salt or derivative thereof, are useful in therapy and prophylaxis, including increasing the Th1:Th2 response ratio, haemorestoration, alleviation of immuno-suppression, cytokine stimulation, treatment of proliferative disorders (e.g. cancer), vaccination, stimulation of the innate immune response and boosting of the activity of endogenous NK cells. | 08-15-2013 |
20130216585 | COMPOSITION AND METHODS FOR QUENCHING FREE RADICALS AND MODULATING INFLAMMATION - Compositions and methods useful in quenching free radicals, the compositions including dihydroquercetin, vitamin C and Arabinogalactan, specifically, larch arabinogalactan, effective to enhance the immune modulating properties of Larch Arabinogalactan by quenching the free radicals that initiate a cascade of oxidative stress and inflammation. | 08-22-2013 |
20130216586 | ANIMAL FEED COMPOSITIONS AND METHODS OF USING THE SAME - Immune function of an animal can be modulated by administration of a composition that includes beta glucan. The beta glucan can be derived from | 08-22-2013 |
20130216587 | POLARIZED SCORPION VENOM SOLUTION AND A METHOD FOR MAKING POLARIZED SCORPION VENOM SOLUTION - The present invention discloses a polarized dilute blue scorpion venom solution and a method for administering dilute scorpion venom solution. The polarized dilute scorpion venom solution provides treatment to various diseases and conditions such as relieving pain, improving immune-system responses, treating cancer, preventing cancer, improving quality of sleep, reducing inflammation, and minimizing negative biological response to chemotherapy and radiation treatment | 08-22-2013 |
20130230559 | NOVEL TACROLIMUS ANALOGUES, A NEUROPROTECTIVE COMPOSITION COMPRISING THE SAME, AN IMMUNOSUPPRESSIVE COMPOSITION COMPRISING THE SAME, A METHOD FOR PREPARING THE SAME, AND A MUTANT FOR PRODUCING THE SAME - The present invention relates to novel tacrolimus analogues, a composition for the prevention or treatment of neurological diseases or immune hypersensitivity disorders comprising the same, a method for preventing or treating neurological diseases or immune hypersensitivity disorders comprising administering the analogues to a subject, a method for preparing the analogues using an isolated modified | 09-05-2013 |
20130230560 | IgA PRODUCTION PROMOTER - To provide an IgA production promoter capable of being easily ingested safely and continually, for example orally and capable of preventing infection by inhibiting the binding of pathogenic microorganisms to alimentary canal mucosa and preventing an allergic reaction by blocking the passage of allergen materials such as pollen and house dust through the wall of the alimentary tract. The present invention consists of an IgA production promoter comprising hydroxypropyl starch as an effective ingredient. The IgA production promoter of the present invention can be safely and continually ingested because the effective ingredient thereof is hydroxypropyl starch used in food and the like, and can prevent infection by inhibiting the binding of pathogenic microorganisms to alimentary canal mucosa and prevent an allergic reaction by blocking the passage of allergen materials such as pollen and house dust through the wall of the alimentary tract. | 09-05-2013 |
20130236495 | PEPTIDES FOR MODULATING T-CELL ACTIVITY AND USES THEROF - The present invention provides methods and materials for treating and preventing autoimmune diseases. In particular, the present invention relates to the discovery that small peptides are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD 154, which is important in inflammation. The present invention also relate to the use of such peptides in reducing the inflammatory response, and in particular, the autoimmune inflammatory response. The present invention also relates to the use of such short peptides to prevent or reverse autoimmune disease, and particular, diabetes, in individuals suffering from such disease. It also relates to methods and materials for detecting T-cells that express CD40 (Th40 cells). Also provided are kits for reducing inflammation, treating autoimmune diseases, or detecting Th40 cells. | 09-12-2013 |
20130243821 | SOYBEAN DERIVED HUMAN THYROGLOBULIN, METHODS OF PRODUCING AND APPLICATIONS THEREOF - The present invention includes novel soybean derived human thyroglobulin, methods of producing human thyroglobulin in plants such as soybean, and novel diagnostic applications for the detection and stratification of endocrine malignancies including thyroid cancer and thyroiditis. The invention also includes the use of soybean-derived human thyroglobulin in affinity matrices to remove autoreactive anti-thyroglobulin antibodies from patient's sera prior to analyses. Moreover, the invention also includes methods and compositons of treating, preventing and or/ameliorating symptoms associated with thyroiditis. | 09-19-2013 |
20130259900 | ADJUVANT SYSTEM FOR VACCINE ADJUVANT - The present invention provides adjuvant compositions that have improved stability, increased potency and which provide an enhanced T | 10-03-2013 |
20130259901 | Neuropeptide Y Treatment of Autoimmune Disease - The present invention provides a method for treating or delaying the onset of an autoimmune condition in a human subject comprising orally administering to the subject at an effective dose of neuropeptide Y. | 10-03-2013 |
20130273113 | IMMUNOGENIC APOPTOSIS INDUCING COMPOSITIONS AND METHODS OF USE THEREOF - The present invention provides methods and compositions for the stimulation of immune responses. In particular, the present invention provides nanoemulsion compositions and methods of using the same for the induction of immune responses (e.g., immunologic cell death/apoptosis (e.g., for the induction of innate and/or adaptive immune responses)). Compositions and methods of the invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., for infectious disease, cancer, autoimmunity, and/or tissue injury (e.g., via alteration of host immune responses))) and research applications. | 10-17-2013 |
20130273114 | PHARMACEUTICAL COMPOSITIONS OF IMMUNOSUPPRESSANTS - The present invention describes immunosuppressant pharmaceutical formulations particularly formulations of mycophenolate salts with pulsatile release behaviour. | 10-17-2013 |
20130287815 | METHODS FOR IN VITRO DIFFERENTIATION OF TH-17+ CELLS - The present invention is directed to an in vitro method for promoting differentiation and proliferation of human T helper lymphocytes that express IL17 (Th-IL17+ cells). The instant method may be used to generate a population of human T helper lymphocytes that express IL17 (Th-IL17+ cells) in vitro. Methods for screening to identify agents capable of modulating Th-IL17+ cell differentiation are also encompassed by the present invention. Isolated, pure populations of homogeneous Th-IL17+ cells that do not express cellular markers characteristic of Th1, Th2, or Treg cells are also encompassed herein. | 10-31-2013 |
20130287816 | P97 PROTEIN AND USES THEREOF AS VACCINE ADJUVANT - Immunogenic compositions comprising a p97 adhesin adjuvant polypeptide, or a nucleic acid encoding said p97 adhesin adjuvant polypeptide, and a heterologous antigen are disclosed. Uses of the p97 adhesin adjuvant polypeptide or nucleic acid, or immunogenic compositions comprising same, for inducing an immune response against a heterologous antigen in a subject are also disclosed. | 10-31-2013 |
20130295141 | MATRIX METALLOPROTEINASE INHIBITORS - The present invention relates to β-hydroxy and amino-substituted carboxylic acids, which act as matrix metalloproteinase inhibitors, particularly diastereomerically pure β-hydroxy carboxylic acids, corresponding processes for their synthesis, and pharmaceutical compositions containing the compounds of the present invention. Compounds of the present invention are useful in the treatment of various inflammatory, autoimmune, and allergic diseases, such as methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the over-expression and over-activation of a matrix metalloproteinase. | 11-07-2013 |
20130295142 | IMMUNOTHERAPY USING ALLO-NKT CELLS, CELLS FOR IMMUNOTHERAPY IN WHICH ALPHA CHAIN OF T-CELL RECEPTOR (TCR) GENE HAS BEEN REARRANGED TO UNIFORM V-ALPHA-J-ALPHA, AND BANKING OF NKT CELLS DERIVED FROM SAID CELLS - The present invention provides an agent for an immunocyte therapy, comprising an NKT cell obtained by differentiating in vitro a cell having the α-chain region of the T cell receptor gene rearranged to uniform Vα-Jα in an NKT cell receptor-specific way, wherein an administration subject is an allogenic individual having MHC gene loci including at least one locus having a genotype different from that of the NKT cell. In addition, the present invention provides a bank of a human cell or an NKT cell derived from said cell, wherein the α-chain region of a T cell receptor (TCR) gene has been rearranged to uniform Vα-Jα. The agent and cell bank of the present invention are useful for the prophylaxis and/or treatment of cancer, infection, an allergic disease or an autoimmune disease. | 11-07-2013 |
20130302377 | STIMULATING IMMUNE RESPONSE - Methods of treatment or prevention of a cancerous or pre-cancerous condition, of slowing or preventing growth of a cancerous condition, of stimulating a cell-mediated immune response, stimulating a Th1 helper T cell response against a pathogen in a mammal and of treating or preventing inflammatory diseases or disorders that involve administration of N-methyl pyrrolidone (NMP) or a physiologically acceptable salt, solvate, tautomer or prodrug thereof are provided. Also provided are formulations of an active agent. | 11-14-2013 |
20130302378 | MATRIX METALLOPROTEINASE INHIBITORS - The present invention relates to β-hydroxy and amino-substituted carboxylic acids, which act as matrix metalloproteinase inhibitors, particularly diastereomerically pure β-hydroxy carboxylic acids, corresponding processes for their synthesis, and pharmaceutical compositions containing the compounds of the present invention. Compounds of the present invention are useful in the treatment of various inflammatory, autoimmune, and allergic diseases, such as methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the over-expression and over-activation of a matrix metalloproteinase. | 11-14-2013 |
20130302379 | Method for Preparing Pharmaceutical Composition for Enhancing Immunity and Pharmaceutical Composition Prepared According to the Method - A method for preparing a pharmaceutical composition for enhancing immunity and a pharmaceutical composition prepared according to the method. The method includes steps of: mixing ginseng ethanol extract with fruit and vegetable fermentation conversion solution to obtain a mixture, namely, the pharmaceutical composition for enhancing immunity; wherein the ginseng ethanol extract is prepared by a following step of: reflux extracting ginseng by ethanol aqueous solution for obtaining the extract, namely, the ginseng ethanol extract; the fruit and vegetable fermentation conversion solution is prepared by following steps of: mixing fruit and vegetable, | 11-14-2013 |
20130309272 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES - The invention relates to compounds of structural formula (I) and structural formula (VI): | 11-21-2013 |
20130315961 | GENERATION OF NOVEL BONE FORMING CELLS (MONOOSTEOPHILS) FROM LL-37 TREATED MONOCYTES - In one embodiment, a monocyte derived bone-forming cell population is provided. In one embodiment, the cell population comprises an isolated monocyte cell population treated with an effective dose of LL-37. In another embodiment, a method of producing a population of monocyte-derived bone-forming cells is provided. The method comprises obtaining a blood sample from a subject; isolating a population of monocytes from the blood sample; treating the isolated monocytes with an effective dose of LL-37; and culturing the LL-37 treated monocytes until they differentiate into the population of monocyte-derived bone-forming cells. In another embodiment, a method of treatment for a bone injury or bone disease is provided. The method comprises administering a therapeutically effective amount of a composition to a subject having the bone injury or disease, the composition comprising a population of monoosteophils. | 11-28-2013 |
20130323284 | USE OF mTOR INHIBITORS TO TREAT BACTERIAL INFECTION - A method for treating a mammal having an infection with an organism that persists intracellularly in a mammalian cell by inducing an autophagy defect includes administering to the mammal an effective dose of a bioavailable agent that restores autophagy function, by inhibition of the mTOR pathway. | 12-05-2013 |
20130323285 | PEPTIDE ADJUVANTS - Adjuvant compositions comprising specific 5mer polypeptides in combination with antigen delivery systems and/or immunostimulatory molecules, such as immunostimulatory nucleic acid sequences, for enhancing the immune response of a coadministered antigen, are described. | 12-05-2013 |
20140004154 | Pharmaceutical Composition Consisting Of RNA Having Alkali Metal As Counter Ion And Formulated With Dications | 01-02-2014 |
20140004155 | 2-AMINOTHIAZOLE DERIVATIVES AND METHODS OF PREPARING AND USING THE SAME | 01-02-2014 |
20140030294 | METHODS FOR INCREASING IMMUNE RESPONSES USING AGENTS THAT DIRECTLY BIND TO AND ACTIVATE IRE-1 - The invention provides, e.g., compositions and methods for increasing activation of immune cells. | 01-30-2014 |
20140037693 | 6"-AMINO-6"-DEOXYGALACTOSYLCERAMIDES - This invention relates to galactosylceramide compounds. | 02-06-2014 |
20140037694 | ADJUVANT FOR TRANSDERMAL OR TRANSMUCOSAL ADMINISTRATION AND PHARMACEUTICAL PREPARATION CONTAINING SAME - The present invention addresses the problem of providing a low-molecular weight adjuvant which can be administered safely without inducing skin irritation or the like by transdermal or transmucosal administration and is for efficiently enhancing the immunogenicity of an antigen. The present invention relates to an adjuvant for transdermal or transmucosal administration, containing at least one member selected from polyhydric alcohols and derivatives thereof including glycerol, glycerol derivatives and the like. | 02-06-2014 |
20140056945 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CANCER BY INDUCING DENDRITIC CELL-LIKE DIFFERENTIATION FROM MONOCYTES TO IMPROVE ANTICANCER IMMUNE ACTIVITY - According to the present invention, a composition for inducing or activating dendritic cell-like cells so as to treat or prevent cancer by immunotherapy is provided. | 02-27-2014 |
20140056946 | METHOD FOR ISOLATION OF POLYSACCHARIDES - The invention relates to a method for production of a preparation from a vegetable material, said preparation being enriched in a polysaccharide with a backbone comprising rhamnogalacturonan-I cores, said method | 02-27-2014 |
20140072598 | MEDICINAL PREPARATION "RENESSANS" HAVING AN ANTIBACTERIAL, ANTI-ULCEROUS AND IMMUNO-MODULATING ACTION - The invention relates to the field of medicine, particularly to medical preparations of anti-bacterial, anti-ulcer and immune simulating effects, which can be used in injection form. The medical preparation “RENESSANS” contains components in the following ratio (wt %): | 03-13-2014 |
20140079737 | USE OF IMMUNOMODULATORY PROTEIN IN PROMOTION OF WOUND HEALING OR TREATMENT OF TISSUE INJURY - The invention provides a method for promoting wound healing or tissue injury treatment in a subject in need thereof, the method comprising administering to the subject an effective amount of one or more fungal immunomodulatory protein (preferably, | 03-20-2014 |
20140079738 | SELF-GELATINIZABLE NUCLEIC ACID - The purpose of the invention of the present application is to a method for preparing a hydrogel composed substantially only of nucleic acids. The invention of the present application provides: a nucleic acid sol-like composition for producing a nucleic acid gel without requiring the use of any nucleic acid ligase, wherein the composition comprises at least two nucleic acid monomers which are partly complementary to each other and are independently selected from the group consisting of a nucleic acid, a nucleic acid derivative, a modified nucleic acid, a compound capable of binding to a nucleic acid in complementary manner and a mixture thereof, one of the nucleic acid monomers has a moiety that constitutes a cohesive protruding end and a complementary nucleotide sequence moiety that can bind to at least one of the other nucleic acid monomers to form a double strand, and the composition contains no nucleic acid ligase; and a nucleic acid gel produced using the composition. | 03-20-2014 |
20140086958 | Biomarker for Selecting Patients and Related Methods - The present invention concerns methods for inducing an immune response to an antigen in a patient for treating human disease by administering an immunogenic composition wherein said patient is selected in a patient population of interest. The present invention further concerns methods for determining whether a subject is or is not susceptible to developing a prophylactic or therapeutic immune response after such treatment. | 03-27-2014 |
20140086959 | METHOD FOR PRODUCING MILK HAVING AN IMMUNOREGULATORY ACTION - A method for screening for a foodstuff providing production of milk having an immunoregulatory action, a foodstuff having an immunoregulatory action, and a method for producing it are provided. A diet or substance that increases or decreases an amount of microRNA present in milk of a mammal is identified by using correlation of microRNA profiles in the milk and a diet ingested by the mammal or a substance contained in the diet as an index to screen for a diet or a substance providing production of breast milk having an immunoregulatory action. | 03-27-2014 |
20140086960 | IMMUNOMODULATORY COMPOUNDS AND TREATMENT OF DISEASES RELATED TO AN OVERPRODUCTION OF INFLAMMATORY CYTOKINES - Method of using immunomodulatory compounds for treating diseases related to an overproduction of inflammatory cytokines, including diseases selected from asthma, atopic dermatitis, allergic rhinitis, prostatitis, inflammatory bowel disease, diabetes, and rheumatoid arthritis, the compounds being of general formula (I): | 03-27-2014 |
20140086961 | USE OF CYCLODEXTRINS IN DIETS, WATER OR VACCINE ADJUVANTS TO BOOST THE IMMUNE SYSTEM OF FISH - The present disclosure describes compositions containing cyclodextrin and methods of using cyclodextrins to stimulate or enhance the immune system and response in fish. Methods of enhancing the efficacy of a fish vaccine by administering cyclodextrin to the fish are also described. | 03-27-2014 |
20140093542 | REGULATORS OF NFAT AND/OR STORE-OPERATED CALCIUM ENTRY - Embodiments of the inventions relate to modulating NFAT activity, modulating store-operated Ca | 04-03-2014 |
20140099341 | Modulated Immunodominance Therapy - The invention involves generating a T cell response to subdominant antigens and using the cells to therapeutically change the cellular homeostasis and nature of the immune response. In a preferred embodiment, the cells are generated outside of the patient avoiding the influence of the patient's immunologic milieu. By stimulating and growing the T cells from a patient in a tissue culture to one or more subdominant antigens and the transplanting them into the patient, if enough cells are expanded and transplanted, the transplanted cells overwhelm the endogenous dominant T cells in the response to either break or induce immune tolerance or otherwise modify the immune response to the cells or organism expressing that antigen. When the memory cells are established they are then reflective of this new immunodominance hierarchy so that the desired therapeutic effect is long lasting. In effect, the transplantation exogenously generated T cells reactive to the subdominant antigens is recapitulating priming and rebalancing the patient's immune response to target previously subdominant antigens in the cells or organism to produce a therapeutic benefit. | 04-10-2014 |
20140147471 | IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE THEREOF - Immunostimulatory compositions and methods of use are described to either enhance or diminish the immune stimulation effects of a honey or honey isolate by recognition of the presence of type II arabinogalactan compounds and utilising this knowledge to tailor the concentration of such compounds thereby adjusting the immune stimulation effects. | 05-29-2014 |
20140170191 | NOVEL DOUBLE-STRANDED RIBONUCLEIC ACIDS WITH RUGGED PHYSICO-CHEMICAL STRUCTURE AND HIGHLY SPECIFIC BIOLOGIC ACTIVITY - A novel form of Rugged dsRNA with a unique composition and physical characteristics was identified with high specificity of binding to TLR3, which conveys an important range of therapeutic opportunities. Unlike the previous known antiviral Ampligen® (poly I, poly C12,U) the new and improved form (poly I, poly C | 06-19-2014 |
20140178439 | CAPTURE OF PATHOGENIC AND NON-PATHOGENIC BIOPOLYMERS AND BIOPARTICLES - A method of preparing a capturing agent for a selected biopolymer or bioparticle, includes the steps of:
| 06-26-2014 |
20140199348 | Anti-Viral Compounds - Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway. | 07-17-2014 |
20140220080 | IgA SECRETION PROMOTER - Provided is a novel IgA secretion promoter useful as a mucosal immunity stimulation agent and a method of promoting IgA secretion in a body of animal to stimulate mucosal immunity. A significant action of promoting IgA secretion was observed in oral administration of indigestible dextrin. | 08-07-2014 |
20140220081 | USE OF A GALACTOSE-DERIVED C-GLYCOSIDE COMPOUND AS AN AGENT FOR ACTIVATING AND REGULATING CUTANEOUS IMMUNITY - The present invention relates to novel galactose derivatives of general formula (I) and their use as agents for stimulating the immune system of the skin and/or as immunoregulators, and for preparing a composition containing a cosmetically or pharmaceutically acceptable medium, intended in particular to prevent and/or limit the appearance of cutaneous immune imbalances, in particular related to environmental stresses. | 08-07-2014 |
20140234378 | Lobster hemolymph as a utility for treatment of mammalian tissue lesions - The invention is crustacean hemolymph as a utility for the pharmaceutical and/or cosmetic treatment of viral and other neoplastic or pre-neoplastic mammalian tissue lesions. The method comprises topically administering to mammalian tissue a formula that is made from lobster hemolymph—neat; or lobster hemolymph extracts; or lobster hemolyph in combination with certain carriers, binders; or as an adjuvant. The hemolymph may be from various species of lobster, | 08-21-2014 |
20140242119 | AMINO ALCOHOL DERIVATIVES FOR THE TREATMENT OF DEMYELINATING PERIPHERAL NEUROPATHIES - The invention provides the use of compound of formula V or formula VI in the treatment of a demyelinating peripheral neuropathy: | 08-28-2014 |
20140242120 | SUBSTITUTED AROMATIC COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES - The invention relates to compounds of structural formula (I): | 08-28-2014 |
20140242121 | NOVEL IMIDAZOLE QUINOLINE-BASED IMMUNE SYSTEM MODULATORS - The present invention relates to a compound of Formula I: or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same; and a method for treating or preventing autoimmunity disease using the same. | 08-28-2014 |
20140248317 | TREHALOSE COMPOUND, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL PRODUCT CONTAINING THE COMPOUND - A trehalose compound having high immunopotentiating activity and low toxicity is represented by formula (1). (In the formula, X and X′ each represents a phenyl, a naphthyl, R | 09-04-2014 |
20140248318 | NATURAL ANTIOXIDANT ANTI-INFLUENZA COMPOSITION - The invention relates to a composition from the extract of | 09-04-2014 |
20140255450 | NOVEL COMPOUNDS AND USES THEREOF FOR TREATING INFLAMMATION AND MODULATING IMMUNE RESPONSES - The present invention provides compounds, and compositions comprising these compounds, which have immunomodulatory activity and/or anti-inflammatory activity. | 09-11-2014 |
20140271726 | COMPOSITIONS AND METHODS FOR PREDICTING HCV SUSCEPTIBILITY TO ANTIVIRAL AGENTS - Provided herein are methods for determining the susceptibility of a hepatitis C virus (HCV) in a patient to anti-viral agents, particularly cyclophilin inhibitors such as cyclosporine A. More particularly, provided herein are methods for determining the amino acid sequence within a region of the HCV NS5A protein and comparing the viral amino acid sequence to that of a reference strain, wherein the existence of at least one variation in the viral genome is indicative that the virus is more or less susceptible to anti-viral agents relative to the reference strain. Also provided are isolated polynucleotide molecules, replicons, and kits that can be used to assay the susceptibility of a particular HCV to an anti-viral agent. | 09-18-2014 |
20140271727 | METHOD OF USING AN ANTIDEPRESSANT FOR INCREASING IMMUNITY OF A SUBJECT AND TREATING CANCER - A method of increasing immunity of a subject by administering an antidepressant to the subject is disclosed in the present invention. Preferably, the antidepressant is mirtazapine. And further, another object of the present invention is related to a method of administering the abovementioned antidepressant to the subject for treating cancer. The present invention tries to find the mechanism of the tumor growth inhibition by mirtazapine, and it may be due to the alteration of the tumor microenvironment, which involves the activation of the immune response and the recovery of serotonin level. | 09-18-2014 |
20140286997 | ARABINOGALACTAN FOR ENHANCING THE ADAPTIVE IMMUNE RESPONSE - The present invention discloses a composition containing Arabinogalactan for enhancing the adaptive immune response in subjects to foreign antigen(s) by administering said composition prior, during and after the phase of exposure to said foreign antigen(s). Furthermore, the present invention relates to a vaccination kit comprising a composition comprising Arabinogalactan and a vaccine. | 09-25-2014 |
20140286998 | Double-Stranded RNA For Immunostimulation - The present invention relates to a ribonucleic acid (RNA) of double-stranded structure which is capable of triggering Toll-like receptor 3 (TLR-3) and which shows an increased serum stability while simultaneously being unable to be processed by the DICER complex. | 09-25-2014 |
20140294897 | POTENT LNA OLIGONUCLEOTIDES FOR THE INHIBITION OF HIF-1A EXPRESSION - The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5′-( | 10-02-2014 |
20140294898 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS - The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases. | 10-02-2014 |
20140302099 | Ophthalmic Composition Containing Cyclosporine And method For Preparing Same - The present invention relates to an ophthalmic composition containing cyclosporine as an active ingredient and comprising propylene glycol, a surfactant, and purified water, and to a method for preparing same. The ophthalmic composition according to the present invention is in the form of a clear and transparent solution, and increases patient compliance due to the absence of side effects, such as cloudy vision or a scorching sensation, and has a high bioavailability due to improved cyclosporine absorbance in the ocular tissue, which is the target organ. | 10-09-2014 |
20140302100 | METHODS AND BIOMARKERS FOR ANALYSIS OF COLORECTAL CANCER - The present invention relates to methods and biomarkers (e.g., gene expression biomarkers) for detection of colorectal cancer in biological samples (e.g., tissue samples, biopsy samples, stool samples, blood samples, plasma samples, serum samples). In some embodiments, methods and biomarkers of the present invention find use in detection of colon cancer and in providing a prognosis to colorectal cancer patients. | 10-09-2014 |
20140308317 | Polymeric Compounds And Methods Of Making And Using The Same - The present disclosure provides compounds, or pharmaceutically acceptable salts thereof, for inhibiting the growth of a microbe; treating a mammal having a microbial infection, malaria, mucositis, an ophthalmic infection, an otic infection, a cancer, or a | 10-16-2014 |
20140308318 | Inhibitors against Endosomal/Lysosomal Enzymes - The present invention relates to a multi-functional protease inhibitor, which may be conjugated to various molecules. The present invention also relates to uses of the protease inhibitor and conjugates thereof. | 10-16-2014 |
20140322276 | METHODS OF TREATING OR PREVENTING NEUROLOGICAL DISEASES - The present disclosure provides a method for treating an inflammatory neurological disease comprising administering a population of cells enriched for STRO-1 | 10-30-2014 |
20140328882 | WHEAT GERM EXTRACT OBTAINED BY PROTEASE HYDROLYSIS AND MEDICAL USE THEREOF - The invention relates to a dried enzymically hydrolyzed plant material, which is capable of immunmodulation, immunoregulation, reducing inflammation and reducing tumor progression. The material can be used in the manufacture of pharmaceutical compositions, dietary supplements, dietary foods for medical purposes, nutraceuticals, in feed materials, and in supplementary feeds. The process for producing the material is also described, as are its use in the modulation, and regulation of immune reactions, reducing inflammation and/or tumor progression. The material can also be used in treatment of several inflammatory disorders. | 11-06-2014 |
20140335130 | AMINO ACID SUPPLEMENTATION FOR A HEALTHY MICROBIOTA ECOSYSTEM - The present invention pertains to a nutritional composition for reconstituting an optimal healthy microbiota ecosystem in humans or animals. In particular, the present invention relates to an ingestible carrier containing specific amino acids designed to favor the growth of bacteria favorable to individuals health or for reducing the risk of developing deleterious events. The invention also pertains to the use of specific amino acids for reconstituting an optimal healthy microbiota ecosystem in humans or animals, in particular in infants, critically ill patients, in the case of chronic diseases or any stresses impacting the gut and in elderly people. | 11-13-2014 |
20140348877 | Lobster hemolymph as a utility for treatment of mammalian tissue lesions - The invention is crustacean hemolymph as a utility for the pharmaceutical and/or cosmetic treatment of viral and other neoplastic or pre-neoplastic mammalian tissue lesions. The method comprises topically administering to mammalian tissue a formula that is made from lobster hemolymph—neat; or lobster hemolymph extracts; or lobster hemolyph in combination with certain carriers, binders; or as an adjuvant. The hemolymph may be from various species of lobster, | 11-27-2014 |
20140363471 | METHOD OF INDUCING AUTOPHAGY AND ACTIVATING TOLL-LIKE RECEPTOR - A method of inducing autophagy in a cell is achieved by contacting the cell with graphene oxide (GO) in an amount effective to induce autophagy in the cell, wherein the cell expresses at least one of TLR-4 (Toll-like receptor 4) and TLR-9 (Toll-like receptor 9). Differences between autophagy triggered by GO and other conventional agonists such as rapamycin have been observed. GO may activate autophagy in some cells that may not be triggered by rapamycin. The cell reveals no apparent apoptosis after treatment of the graphene oxide. A method of activating a Toll-like receptor in a cell is also herein provided. | 12-11-2014 |
20140363472 | METHODS FOR PREDICTING THE SURVIVAL TIME OF A PATIENT SUFFERING FROM A SOLID CANCER BASED ON DENSITY OF B CELLS - The present invention relates to a method for predicting the survival time of a patient suffering from a solid cancer comprising the steps consisting of i) determining the density of B cells at the invasive margin of the tumor (im) in a tumor tissue sample obtained from said patient, ii) comparing said density with a predetermined reference value and iii) providing a good prognosis when the density of B cells at the invasive margin of the tumor is higher than the predetermined reference value and a poor prognosis when the density of B cells at the invasive margin of the tumor is lower than the predetermined reference value. | 12-11-2014 |
20140370060 | Tear Film Stability - The present invention relates to a method of stabilising a tear film in an individual having an ocular surface inflammatory disorder by providing a compound to an ocular surface of the individual to reduce the synthesis of a cholesterol by a meibum-producing tissue. | 12-18-2014 |
20150017210 | Gene Signature Predicts Adenocarcinoma Prognosis and Therapeutic Response - The present invention is drawn to methods of predicting prognosis of, and therapeutic response in, carcinoma of the lung. | 01-15-2015 |
20150017211 | DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS - Provided are formulations, compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the delivery of biological moieties, and are useful for production of proteins. | 01-15-2015 |
20150050319 | NATURAL SAPONIN-BASED SYNTHETIC IMMUNOADJUVANTS - The present disclosure encompasses QS-21-based structurally-defined adjuvants to address the need for stronger, safer, and easier-to-access adjuvants. The new compositions can provide tools for addressing long-standing mechanistic questions concerning saponin immune-potentiation through structure-activity-relationship (SAR) studies. Most advantageously, the compounds of the disclosure may be formulated into pharmaceutically acceptable compositions, including vaccines that may be delivered to a subject human or animal subject. The compounds can then act as, for example, an adjuvant to augment an immunological response to a vaccine immunogen. | 02-19-2015 |
20150050320 | COMPOSITIONS FOR AND METHODS OF DIET SUPPLEMENTATION - A composition for diet supplementation to improve gut microflora is disclosed. The composition includes a prebiotic source and source of nucleotides, such as an extract of yeast. Also disclosed are methods of diet supplementation that include administering compositions of the invention to an individual. | 02-19-2015 |
20150056253 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF - Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to kill or reduce the growth of microorganisms. Such compositions and methods include the use of modified messenger RNAs, and are useful to treat or prevent microbial infection, or to improve a subject's heath or wellbeing. | 02-26-2015 |
20150064220 | METHODS FOR MODULATING CELL-MEDIATED IMMUNITY USING HUMAN MILK OLIGOSACCHARIDES - Disclosed are methods of enhancing cell-mediated immunity in an individual using nutritional compositions including human milk oligosaccharides. The human milk oligosaccharides are sialylated human milk oligosaccharides, fucosylated human milk oligosaccharides, or a combination of both. The human milk oligosaccharides may enhance T-cell mediated responses and T-cell regulatory responses. | 03-05-2015 |
20150064221 | COMPOUNDS HAVING IMMUNOMUDULATOR ACTIVITY - The present invention is directed to methods of suppressing an immune response in a subject in need thereof comprising administering a therapeutically effective amount of a compound having the following formula: | 03-05-2015 |
20150064222 | NUTRITIONAL COMPOSITIONS FOR ENHANCING IMMUNE FUNCTION - The present disclosure relates to nutritional compositions for pediatric subjects, such as children's nutritional products and infant formulas, comprising a protein source, a fat source, and a source of β-1,3-glucan. | 03-05-2015 |
20150071968 | IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF MANUFACTURE - Immune-stimulatory compositions and methods of manufacture are described with an unexpectedly greater immunostimulatory effect on the immune system than the individual components alone. The compositions include a combination of arabinogalactan protein (AGP) compounds, particularly those derived from honey or with similar activity to honey derived AGP's along with apisimin proteins, peptides or functional fragments thereof, particularly those isolated from royal jelly or apisimin produced via recombinant methods. | 03-12-2015 |
20150093417 | Compositions And Methods For Inhibiting Expression Of CD45 Gene - The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the CD45 gene. | 04-02-2015 |
20150104482 | USE OF CPG OLIGONUCLEOTIDES CO-FORMULATED WITH AN ANTIBIOTIC TO ACCELERATE WOUND HEALING - Pharmaceutical compositions are provided that include an antibiotics, but that include ingredients that counteract the effect of that antibiotic on wound healing, without altering the bactericidal properties of the antibiotic. These pharmaceutical compositions include an effective amount of 1) an imidazoquinoline having toll-like receptor 7 (TLR7) ligand activity, 2) an immunostimulatory K-type CpG oligodeoxynucleotide (ODN) comprising an unmethylated CpG motif, 3) an antibiotic, and 4) a surfactant, wherein the composition is formulated for topical administration. Methods for accelerating wound healing are also provided. These methods include topically administering the disclosed compositions. The wound can be in the skin or in the eye. | 04-16-2015 |
20150104483 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION - The present invention provides a novel therapeutic drug for cerebral infarction, which contains a piperazine compound as an active ingredient. The compound of the present invention can be provided as a novel therapeutic drug for cerebral infarction having an effect of suppressing brain injury volume or improving neurological deficit, since it suppresses production of plural inflammatory cytokines and chemokines present in the brain such as TNF-α, IL-1β, IL-6 and MCP-1 and the like. | 04-16-2015 |
20150118266 | COMPOSITION FOR PREVENTING, IMPROVING, OR TREATING IMMUNE DISEASES COMPRISING NATURAL EXTRACTS AS ACTIVE INGREDIENTS - The present invention provides a composition for preventing, improving, or treating Th1-mediated immune diseases or Th2-mediated immune diseases, an antihistamine composition, and an anti-inflammatory composition. The present invention provides a method for preventing, improving, or treating Th1-mediated immune diseases or Th2-mediated immune diseases, a method for inhibiting the release of histamine, and a method for preventing, improving, or treating inflammatory disorders. The composition according to the present invention has excellent inhibitory activities for IL-4 generation, the degranulation of mast cells, COX-2, 15-NOX, and the passing of allergens from through an intestinal epithelial cell layer, or an excellent Treg cell inducing activity. Further, the present invention provides a detailed mechanism of action of a natural substance and a food-drived antiallergenic substance, and provides stability, a reduction in production costs, and improved convenience of use by using a natural substance as a material. | 04-30-2015 |
20150118267 | METHOD OF USING THEAFLAVIN - A method for enhancing the immune system or for treating an infectious disease, the method includes administering to a subject in need thereof an effective amount of theaflavins, analogs thereof, or prodrugs thereof, or includes administering to a subject a composition comprising a physiologically acceptable carrier and an effective amount of an extract of tea. | 04-30-2015 |
20150125490 | COMPOSITIONS AND METHODS FOR LUNG REGENERATION - Described herein are stein cells and related factors for treating degenerative and inflammatory disorders of lung tissue. | 05-07-2015 |
20150125491 | Immunomodulating Cyclic Compounds - The present invention relates to novel cyclic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them. | 05-07-2015 |
20150125492 | COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS - Embodiments of the invention are directed to methods of treating, inhibiting or attenuating a microbial infection in an individual who has or is at risk for developing such an infection, comprising the step of administering an effective amount of a StIR composition to the individual. | 05-07-2015 |
20150132342 | NOVEL IMMUNE ACTIVATORS: SUBSTITUTE 4-AMINOQUINAZOLINES - Provided herein are compounds and methods for modulating an immune response in a subject in need thereof. Further provided herein are compounds and methods for modulating a toll-like receptor protein. | 05-14-2015 |
20150132343 | SYSTEM AND METHOD FOR THE DETECTION AND TREATMENT OF INFECTION BY A MICROBIAL AGENT ASSOCIATED WITH HIV INFECTION - A method of treating a patient, comprising administering at least one antibiotic, e.g., doxycycline and ciprofloxacin, sufficient to substantially treat an intracellular bacterial organism present in at least erythrocytes, e.g., over a course of at least two weeks; and subsequently administering at least one immunostimulant, e.g., which directly or indirectly increases levels of immunostimulatory cytokines in the patient, and at least one antioxidant, e.g., glutathione, to effectively treat a coinfection of the patient with a virus. The intracellular bacterial organism may be a rickettsiales-like organism, and the virus may be HIV. | 05-14-2015 |
20150140042 | Polyinosinic-Polycytidylic Acid (Poly (I:C)) Formulations for the Treatment of Upper Respiratory Tract Infections - The present invention concerns a composition comprising micro particles of polyinosinic-polycytidylic acid (Poly (I:C)) and a carrier polymer selected from starch, alginate, blanose or DPPC (dipalmitoylphosphatidylcholine) for use in preventing and/or treating viral infections of the upper respiratory tract or the common cold and a device, preferably a nasal delivery system, comprising said composition for use by a patient in need to prevent and/or treat infections or the common cold. | 05-21-2015 |
20150140043 | IMMUNOMODULATORY METHODS USING NOTCH AGONISTS - The invention relates to materials and methods for regulating immune pathways using NOTCH and NOTCH agonists. In particular, said agonists may be used in methods for sensitizing CD4+ CD25− cells to CD4+ CD25+ cell-mediated immunosuppression, for enhancing the TGF-β response of CD4+ CD25− cells. | 05-21-2015 |
20150140044 | IMMUNOMODULATION USING PLACENTAL STEM CELLS - The present invention provides methods of immunomodulation using placental stem cells and placental stem cell populations. The invention also provides methods of producing and selecting placental cells and cell populations on the basis of immunomodulation, and compositions comprising such cells and cell populations. | 05-21-2015 |
20150147357 | Compositions for Sensitive Skin - Disclosed are compositions and methods for their use that include a combination of hydrolyzed algin, escin, | 05-28-2015 |
20150147358 | Methods for modulating immune responses - The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents. | 05-28-2015 |
20150290194 | THERAPEUTIC USES OF SELECTED PYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY - Uses of pyrimidines with anti-Mer tyrosine kinase activity as anti-infective agents, immunostimulatory and immunomodulatory agents, anti-cancer agents (including against MerTK −/− tumors and ITD and TKD mutant forms of Acute Myeloid Leukemia (AML)), and as adjunctive agents in combination with chemotherapeutic, radiation or other standard of care for neoplasms. | 10-15-2015 |
20150291534 | COMPOUNDS FOR TREATING HIV AND METHODS FOR USING THE COMPOUNDS - Disclosed herein are embodiments of a compound capable of treating HIV. In particular disclosed embodiments, the compound is capable of inhibiting Nef, such as by acting as antagonists of HIV Nef function. Also disclosed are embodiments of a method of making the compound, embodiments of a method of using the compound, and embodiments of a method of identifying HIV Nef antagonists. The disclosed compound may be used alone or in combination with other pharmacologically active agents in order to promote reducing drug resistance and/or cumulative toxicity. | 10-15-2015 |
20150291549 | Compounds Useful as Immunomodulators - The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases. | 10-15-2015 |
20150299204 | NOVEL COMPOUNDS - The present invention relates to compounds of formula (I) and salts thereof: | 10-22-2015 |
20150299255 | COMPOSITIONS AND METHODS FOR MODULATING INNATE AND ADAPTIVE IMMUNE SYSTEMS - Compositions and methods for modulating the innate and adaptive immune systems in a subject. The compositions and methods may inhibit the function of inhibitory receptors and enhance activity of activating receptors. The method typically includes the steps of: administering to the subject a composition having a therapeutic peptide or multivalent polypeptide having multiple copies of the therapeutic peptide in an amount sufficient to increase activity of the immune system in the subject. Compositions may include a carrier; at least one agent selected from the group consisting of: an anti-inflammatory agent, a cytotoxic T cell proliferation agent, and/or a NK cell proliferation agent; and a selected therapeutic peptide or multivalent polypeptide. The compositions may also include an immunoglobulin admixed therewith to enhance passive immunoprotection. | 10-22-2015 |
20150299710 | Inhibitory Oligonucleotide and Use Thereof - The inhibitory oligonucleotides (ODNs) which strongly block NF-κB activation induced by TLR9 agonists and TLR7 agonists are provided. The production of proinflammatory cytokines, such as interleukin-6 and tumor necrosis factor alpha, is inhibited by the inhibitory-ODNs. Interferon production from human PBMC induced by TLR9 agonist is prevented by the inhibitory-ODNs. These ODNs can be used as a remedy for the treatment of immune-mediated disorders such as rheumatoid arthritis, systemic lupus erythematosus (SLE), sepsis, multiple organ dysfunction syndromes. | 10-22-2015 |
20150301046 | METHOD OF REVERSIBLY STAINING A TARGET CELL - The present invention relates to methods of treating a subject with a population of target cells defined by the presence of a specific receptor molecule on the surface; wherein the population of target cells is isolated by a method of reversibly staining the target cells with a detectable label. | 10-22-2015 |
20150306213 | HMGB1-DERIVED PEPTIDES ENHANCE IMMUNE RESPONSE TO ANTIGENS - The invention provides an immunostimulatory peptide containing the amino acid sequence SAFFLFCSE and uses thereof. | 10-29-2015 |
20150306215 | LPRG AS A CHAPERONE OF IMMUNE ADJUVANTS - An adjuvant combination that stimulates immune activation or response includes a hydrophobic immune adjuvant and a pathogen derived lipoprotein that chaperones the hydrophobic immune adjuvant to an immune receptor. | 10-29-2015 |
20150306250 | FACTOR VIII MUTATION REPAIR AND TOLERANCE INDUCTION - Methods of treating hemophilia A in a subject with an F8 gene mutation, wherein the F8 gene is repaired and the resultant repaired gene, upon expression, confers improved coagulation functionality to the encoded FVIII protein of the subject compared to the non-repaired F8 gene. The invention also includes methods of inducing immune tolerance to a FVIII replacement product ((r)FVIII) in a subject having a FVIII deficiency, wherein the F8 gene mutation is repaired and the repaired gene, upon expression, provides for the induction of immune tolerance to an administered replacement FVIII protein product. The invention also includes isolated nucleic acids, vectors, recombinant viruses, cells, and pharmaceutical compositions to repair the F8 gene. | 10-29-2015 |
20150320754 | COMBINATION THERAPIES - Provided herein are pharmaceutical compositions comprising a phosphatidylinositol 3-kinase inhibitor, or pharmaceutically acceptable form thereof, in combination with a second agent, or a pharmaceutically acceptable form thereof, wherein the second agent is chosen from one or more of 1) a CDK4/6 inhibitor, 2) an HDAC inhibitor, 3) a MEK inhibitor, 4) a mTOR inhibitor, 5) an AKT inhibitor, 6) a proteasome inhibitor, 7) an immunomodulator, 8) a glucocorticosteroid, 9) a BET inhibitor, 10) an epigenetic inhibitor, 11) a PI3K alpha inhibitor, 12) a topoisomerase inhibitor, or 13) an ERK inhibitor. Also provided herein are methods of treatment comprising administration of the compositions, and uses of the compositions, e.g., for treatment of cancer. | 11-12-2015 |
20150320858 | QUIL A FRACTION WITH LOW TOXICITY AND USE THEREOF - Fraction A of Quil A can be used together with at least one other adjuvant for the preparation of an adjuvant composition, where the included adjuvant components act synergistically to enhance level of immune response and have synergistic immunomodulating activity on the co-administered antigens or immunogens. Other adjuvants can comprise saponins, naturally occurring, synthetic or semisynthetic saponin molecules; e.g. saponins and saponin fractions from Quil A, cell wall skeleton, block polymers, TDM, lipopeptides, LPS and LPS-derivatives, Lipid A from different bacterial species and derivatives thereof, e.g., monophosphoryl lipid A, CpG variants, CT and LT or fractions thereof. | 11-12-2015 |
20150322169 | Enhancing Activity of CAR T Cells by Co-Introducing a Bispecific Antibody - The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a T cell, genetically modified to express a chimeric antigen receptor (CAR), a bispecific antibody, or a combination thereof to a subject. The CAR and bispecific antibody of the invention can comprise a human antibody, a humanized antibody, or antigen-binding fragments thereof. | 11-12-2015 |
20150335637 | COMPOSITIONS AND METHODS FOR TREATING CUTANEOUS T CELL LYMPHOMA - The present invention provides methods for treating a subject with cutaneous T cell lymphoma (CTCL). In certain embodiments, a subject is administered an effective amount effective of an IRM compound wherein at least one symptom or clinical sign of CTCL is ameliorated. The present invention further includes a method of increasing a cell-mediated immune response of a cell population that includes cells affected by CTCL. In certain embodiments, an effective amount of the cell population is contacted with an IRM compound wherein at least one cell-mediated immune activity of the cell population is increased. | 11-26-2015 |
20150337310 | SPLICE MODULATING OLIGONUCLEOTIDES THAT INHIBIT CANCER - A method of treating cancer in a subject is provided. The method includes administering a splice modulating oligonucleotide to the subject in an amount effective to provide a therapeutic benefit to the subject. In the method, the oligonucleotide modifies splicing of a pre-mRNA encoding a polypeptide, and either: reduces expression of the polypeptide if the polypeptide promotes cancer cell survival, proliferation, and/or metastasis, or promotes angiogenesis, or a combination thereof; or increases expression of the polypeptide if the polypeptide inhibits cancer cell survival, proliferation and/or metastasis, or inhibits angiogenesis, or a combination thereof. Similar methods of treating diseases involving prolactin or the prolactin receptor are also provided. | 11-26-2015 |
20150342956 | METHODS OF TREATMENT FOR CONDITIONS MEDIATED BY SUBSTANCE P - Methods for treating conditions mediated by substance P, including conditions resulting from an inappropriate anti-parasitic immune response, are described. | 12-03-2015 |
20150342995 | IMMUNOLOGICAL FUNCTION ENHANCING AGENT - A method for enhancing immune function of an animal other than human includes administering an immune function enhancing agent that contains activated lymphocytes to the animal, wherein the animal is an allogeneic animal that belongs to the same species of a donor animal, from which the activated lymphocytes are derived. The immune function enhancing agent is produced by: isolating lymphocytes from the donor animal; obtaining the activated lymphocytes by amplifying and activating the isolated lymphocytes; and producing the immune function enhancing agent using the activated lymphocytes. The animal is different from the donor animal. The animal is a mammal, whose leukocyte antigen is not identical to a leukocyte antigen of the donor animal. Antibodies and immune cells of the animal do not transfer from mother to fetus through placenta. | 12-03-2015 |
20150342996 | Method of Providing Cellular Based Immune Enhancement for Restoring Immunity and Preventing Age Related Diseases - A new and useful method is provided, for enhancing the immune system of a donor/recipient. Stem cells are collected from the donor/recipient at a time that the donor/recipient appears to have a healthy immune system, taking into consideration the age of the donor/recipient and the characteristics of a healthy immune system for a donor/recipient of that age. The stem cells are processed and stored in a condition that enables the stem cells to be later administered to that donor/recipient in predetermined amounts, in serial (consecutive) fashion, over predetermined time intervals, and at the later request of the donor/recipient, the stem cells are administered to the donor/recipient in serial (consecutive) fashion, over predetermined time intervals, to enhance the donor/recipient's immune system thereby preventing formation of age related diseases that are caused by rundown immune system. The practice of the present invention results in replenishing the hematopoietic system and primarily rebuilding the immune system in an aged individual. Also noteworthy, it refreshes the repertoire of stem cells, which are at the point of exhaustion, bringing about extension of life span and can also be used for improvement of cognitive functions of the donor/recipient. | 12-03-2015 |
20150343078 | TARGETED SENSITIZATION OF NON-DEL(5q) MALIGNANT CELLS - Disclosed are molecules for treating non-del(5q) MDS that mimic allelic deficiency in del5q MDS to sensitize the malignant clones of patient without del(5q). The disclosed molecule contains an inhibitor of Cdc25C, an inhibitor of PP2Acα, or a combination thereof, and a toll like receptor-9 (TLR9) targeting ligand. The molecule can also contain lenalidomide, or an analogue or derivative thereof. Also disclosed is a composition comprising the disclosed molecule in a pharmaceutically acceptable carrier. Also disclosed is a method for treating non-del(5q) meylodysplastic syndrome (MDS) in a subject by administering to the subject a therapeutically effective amount of the disclosed pharmaceutical composition. | 12-03-2015 |
20150344884 | INHIBITORY OLIGONUCLEOTIDES AND THEIR USE IN THERAPY - Inhibitory oligonucleotide having the general formula: | 12-03-2015 |
20150361397 | METHOD FOR GENERATION OF REGULATORY T-CELLS USING FACTORS SECRETED BY iNKT CELLS - The current invention concerns the use of PIP or S100A8 for the generation of regulatory T cells. The current invention provides a method of generating regulatory T cells by contacting immature DC with PIP or S100A8 to produce tolerogenic DC and further contacting naïve T cells to the tolerogenic DC to produce regulatory T cells. The invention also concerns PIP protein where immature DC contacted with PIP produce tolerogenic DC that induce conversion of naïve T-cells into regulatory T cells. The invention also concerns S100A8 protein where immature DC contacted with S100A8 produce tolerogenic DC that induce conversion of naïve T-cells into regulatory T cells. The invention also provides methods for identification of factors secreted by iNKT cells that induce conversion of immature DC into tolerogenic DC. The subject invention also concerns using regulatory T cells for treatment and/or management of cancer or the diseases of the immune system. | 12-17-2015 |
20150366909 | METHODS FOR EXPANSION OR DEPLETION OF T-REGULATORY CELLS - The invention features methods of producing compositions enriched in Tregs and methods for treating immunological disorders using these compositions. The invention also features methods for producing compositions enriched in lymphocytes and depleted of Tregs and the use of these compositions in the treatment of proliferative disorders. | 12-24-2015 |
20150366927 | WATER DISPERSIBLE COMPOSITION AND METHOD FOR PREPARING SAME - The invention pertains to a water dispersible, preferably a powder composition of water extractible bioactive components of exclusively fruit or vegetable or plant origin. These components are obtainable by: a) subjecting a selected fruit or vegetable or plant material to homogenisation in weak alkaline conditions and at moderate temperature; b) separating the liquid extract from the homogenised mass and subsequently bringing it to neutrality; and c) eventually concentrating or drying, preferably by freeze drying, the neutralized liquid extract. The composition can be used as primary composition in the preparation of a food product for oral administration, a food supplement, a pet food product, a pet food supplement, a cosmetic preparation or a pharmaceutical preparation. | 12-24-2015 |
20150368316 | A SELECTIVE HIGH-AFFINITY IMMUNE STIMULATORY REAGENT AND USES THEREOF - Isolated polypeptides comprising a mutant programmed cell death 1 (PD-1) polypeptide and fusion polypeptides comprising an isolated mutant PD-1 polypeptide fused to an immunoglobulin domain polypeptide are provided. Further provided are methods of using a composition comprising the fusion polypeptide for stimulating T cell activation for treating disorders including a tumor or an infection. | 12-24-2015 |
20150374715 | EP2 AND EP4 AGONISTS AS AGENTS FOR THE TREATMENT OF INFLUENZA A VIRAL INFECTION - The present invention is directed to the use of EP2 and/or EP4 agonists as therapeutics for the treatment of diseases associated with influenza A viruses, such as for example H5N1 and mutations thereof. | 12-31-2015 |
20150376214 | HETEROCYCLYL-PYRIDINYL-BASED BIPHOSPHONIC ACID, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF - The present invention relates to novel compounds, compositions containing same and methods for inhibiting human farnesyl pyrophosphate synthase or for the treatment or prevention of disease conditions using said compounds; | 12-31-2015 |
20160000907 | NEOSEPTINS: SMALL MOLECULE ADJUVANTS - A MD-2:TLR4 complex agonist compound is disclosed whose structure corresponds to Formula (I), as defined within. Also disclosed are a method of its preparation and use, as well as a pharmaceutical composition containing the same. | 01-07-2016 |
20160002364 | Lactic Acid Bacterium Growth Enhancer, Regulatory T-Cell Number Increasing Agent, Method of Enhancing Growth of Lactic Acid Bacterium, Method of Increasing Number of Regulatory T-Cells, Method of Evaluating Regulatory T-Cell Number Increasing Effect, and Method of Evaluating Lactic Acid Growth Enhancing Effect - A growth enhancer for | 01-07-2016 |
20160008331 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | 01-14-2016 |
20160008388 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | 01-14-2016 |
20160008397 | IMMUNOMODULATION BY CONTROLLING EXPRESSION LEVELS OF MICRORNAS IN DENDRITIC CELLS | 01-14-2016 |
20160015705 | TREATMENT OF T-CELL MEDIATED DISEASES - The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions. | 01-21-2016 |
20160024175 | CHEMOTHERAPY-RESISTANT IMMUNE CELLS - Embodiments of the disclosure include compositions and methods useful for treating cancers that are sensitive to a chemotherapy, such as temozolomide. The methods allow effective cell immunotherapy to be used with chemotherapy when the cell immunotherapy is susceptible to being rendered ineffective by the chemotherapy. In specific aspects, the cancer is being treated by temozolomide (TMZ) and tumor antigen-specific T-cells that are resistant to TMZ. | 01-28-2016 |
20160032384 | USE OF SHROOM3 IN CHRONIC KIDNEY DISEASE AND CHRONIC ALLOGRAFT NEPHROPATHY - A method for identifying the risk of developing Chronic Allograft Nephropathy (CAN) in a patient that received a kidney transplant from a donor which comprises identifying the race of the donor; determining the levels of SHROOM 3 expression in a kidney biopsy specimen obtained from the patient at a predetermined time after transplant; comparing the level of SHROOM 3 expression in the biopsy specimen with the levels of SHROOM 3 expression in a control; determining if the level of SHROOM 3 expression in the allograft is significantly higher than in the control, and diagnosing the patient as being at risk for CAN if the level of SHROOM 3 expression in the specimen is significantly higher than in the control. | 02-04-2016 |
20160038447 | MODULATION OF REGULATORY T CELLS VIA G-COUPLED PROTEIN RECEPTOR 43 - Disclosed herein are compositions and methods that are useful for inducing the development of regulatory T cells (T | 02-11-2016 |
20160038529 | COMBINATION THERAPY FOR MDS - Disclosed are compositions and methods for the treatment of disorders such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The disclosed methods include administering to an individual in need of such treatment a composition that may include an IRAK1/4 inhibitor. In other aspects, the method may include administration of a BLC2 inhibitor. | 02-11-2016 |
20160039875 | INSULIN INDEPENDENCE AMONG PATIENTS WITH DIABETES UTILIZING AN OPTIMIZED HAMSTER REG3 GAMMA PEPTIDE - Embodiments of the present invention provide for novel therapies, pharmaceutical compositions and methods for insulin independence utilizing a new optimized hamster Reg3 gamma peptide, which is new to the art and has not previously been considered for development in the 30 year history since its discovery. Methods, pharmaceutical compositions and therapies novel to the prior art are utilized in this invention to render patients with recent onset and existing type 1 diabetes insulin independent by an optimized hamster Reg3 gamma peptide and an immune tolerance agent for type 1 patients to become insulin independent and used alone without an immune tolerance agent for type 2 diabetes. While not wishing to be bound by theory, optimized Reg3 gamma peptides increases beta cell generation by its demonstrated properties shown within of transforming ductal pancreatic cells into new islets. | 02-11-2016 |
20160039876 | INSULIN INDEPENDENCE AMONG PATIENTS WITH DIABETES UTILIZING AN OPTIMIZED HAMSTER REG3 GAMMA PEPTIDE - Embodiments of the present invention provide for novel therapies, pharmaceutical compositions and methods for insulin independence utilizing a new optimized hamster Reg3 gamma peptide, which is new to the art and has not previously been considered for development in the 30 year history since its discovery. Methods, pharmaceutical compositions and therapies novel to the prior art are utilized in this invention to render patients with recent onset and existing type 1 diabetes insulin independent by an optimized hamster Reg3 gamma peptide and an immune tolerance agent for type 1 patients to become insulin independent and used alone without an immune tolerance agent for type 2 diabetes. While not wishing to be bound by theory, optimized Reg3 gamma peptides increases beta cell generation by its demonstrated properties shown within of transforming ductal pancreatic cells into new islets. | 02-11-2016 |
20160051585 | COMBINED PROTEIN SUPPLEMENTS - Protein supplements that include proteins from animal products, such as whey and eggs, are disclosed. Such a protein supplement may also include one or more immune modulators, such as transfer factor and/or nanofraction immune modulators. | 02-25-2016 |
20160060208 | GLUTAMATE DERIVATIVES FOR TOPICAL USE AS IMMUNOMODULATORY ACTIVE INGREDIENT - The present invention relates to L-glutamate-derived compounds of general formula (1) in which the R radical is a linear or branched C | 03-03-2016 |
20160060266 | Tricyclic Compounds as Inhibitors of Immunosuppression Mediated By Tryptophan Metabolization - Presently provided are inhibitors of IDO and TDO and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase and tryptophan 2,3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosuppression associated with an infectious disease. | 03-03-2016 |
20160060367 | REFINED PRODUCT OBTAINED FROM RICE HULL AND PREPARATION PROCESS AND USE THEREOF - Disclosed herein is a refined product obtained from a rice hull, which consists essentially of a type II arabinogalactan having a number average molecular weight in the range of 56 to 103 kDa. Also disclosed are a process for producing the refined product and use of the refined product for enhancing the biological activity of innate immune cells, as well as for treating allergy and cancer. | 03-03-2016 |
20160067293 | EURYCOMA LONGIFOLIA EXTRACT AND ITS USE IN ENHANCING AND/OR STIMULATING IMMUNE SYSTEM - The present invention discloses the use of a composition comprising an effective amount of an extract of | 03-10-2016 |
20160074427 | METHODS AND COMPOSITIONS FOR ATTENUATING GENE EXPRESSION MODULATING ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSES - Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants. | 03-17-2016 |
20160074508 | COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS - Embodiments of the invention are directed to methods of treating, inhibiting or attenuating a microbial infection in an individual who has or is at risk for developing such an infection, comprising the step of administering an effective amount of a StIR composition to the individual. | 03-17-2016 |
20160074531 | METHODS AND COMPOSITIONS FOR ATTENUATING GENE THERAPY ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSES - Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants. | 03-17-2016 |
20160074532 | METHODS AND COMPOSITIONS FOR ATTENUATING GENE EDITING ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSES - Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants. | 03-17-2016 |
20160075741 | CYCLOSPORINE ANALOGUE MIXTURES AND THEIR USE AS IMMUNOMODULATING AGENTS - The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISA | 03-17-2016 |
20160083442 | INHIBITORS OF THE T CELL-SPECIFIC ALTERNATIVE P38 ACTIVATION PATHWAY AND METHODS OF USE - In T lymphocytes, p38 mitogen activated protein kinase (MAPK) can be activated through an alternative pathway that involves phosphorylation at tyrosine 323. Disclosed herein is the identification of a minimal region of the growth arrest and DNA damage-inducible alpha (Gadd45α) protein that is required for binding to and inhibition of tyrosine 323-phosphorylated p38 in T cells. The disclosed Gadd45α polypeptides inhibit proliferation of T cells in response to T cell receptor stimulation, inhibit differentiation of T cells into Th1 or Th17 cells, inhibit the production of proinflammatory cytokines, and reduce tumor formation and growth of inflammatory cancers, such as pancreatic cancer. | 03-24-2016 |
20160090395 | PHOSPHOLIPID DRUG ANALOGS - Provided in some embodiments are compositions comprising a compound having a structure according to Formula A or Formula B: | 03-31-2016 |
20160097037 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS - Ex vivo and in vivo methods of expansion of renewable stem cells, expanded populations of renewable stem cells and their uses. | 04-07-2016 |
20160101047 | ADULT AND NEONATAL STEM CELL THERAPY TO TREAT DIABETES THROUGH THE REPAIR OF THE GASTROINTESTINAL TRACT - The anatomic and functional arrangement of the gastrointestinal tract suggests an important function of this organ is its ability to regulate the trafficking of metabolites as well as control the equilibrium between tolerance and immunity through gut-associated lymphoid tissue, the neuroendocrine network, and the intestinal epithelial barrier. Combining nucleated cells from various tissues and introducing them directly into the small intestine will have a positive effect on diabetes. | 04-14-2016 |
20160101173 | AQUEOUS GEL FORMULATIONS CONTAINING IMMUNE RESPONSE MODIFIERS - Aqueous gel formulations, including an immune response modifier (IRM), such as those chosen from imidazoquinoline amines, tetrahydroimidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, imidazonaphthyridine amines, imidazotetrahydronaphthyridine amines, oxazoloquinoline amines, thiazoloquinoline amines, oxazolopyridine amines, thiazolopyridine amines, oxazolonaphthyridine amines, thiazolonaphthyridine amines, pyrazolopyridine amines, pyrazoloquinoline amines, tetrahydropyrazoloquinoline amines, pyrazolonaphthyridine amines, tetrahydropyrazolonaphthyridine amines, and 1H-imidazo dimers fused to pyridine amines, quinoline amines, tetrahydroquinoline amines, naphthyridine amines, or tetrahydronaphthyridine amines, are provided. Methods of use and kits are also provided. | 04-14-2016 |
20160102122 | Immunomodulators - The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases. | 04-14-2016 |
20160113901 | Cyclic Peptidomimetic Compounds as Immunomodulators - The present invention relates to cyclic peptidomimetic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them. | 04-28-2016 |
20160113955 | Compositions And Methods For Immunotherapy - The present invention provides novel immunotherapeutic compositions and methods useful for treating or preventing microbial infections, weakened immune systems, diseases in which cells have become obligately anerobic and cellular proliferative disorders including cancer. The immunotherapeutics herein use benzaldehyde derivatives, precursors and intermediaries alone or in combination with additional therapeutic agents to stimulate the immune system and inhibit cellular proliferation. The immunotherapeutics of the present invention are particularly useful in the treatment of microbial infections and cellular proliferative disorders which are resistant to traditional methods of treatment such as antibiotics and chemotherapy | 04-28-2016 |
20160115479 | Predictive Biomarker for Cancer Therapy - The present invention relates generally to the identification of patients suffering from cancer whether they will respond to specific therapies. More particularly the invention relates to a method and means for identifying responder to a therapy TLR-9 agonists. | 04-28-2016 |
20160128960 | AMINO ACID SUPPLEMENTATION FOR A HEALTHY MICROBIOTA ECOSYSTEM - A nutritional composition is used to reconstitute an optimal healthy microbiota ecosystem in humans or animals. In particular, an ingestible carrier contains specific amino acids designed to favor the growth of bacteria favorable to individuals health or for reducing the risk of developing deleterious events. In another aspect, specific amino acids are used to reconstitute an optimal healthy microbiota ecosystem in humans or animals, in particular in infants, critically ill patients, in the case of chronic diseases or any stresses impacting the gut and in elderly people. | 05-12-2016 |
20160136204 | PRODUCTION AND THERAPEUTIC USES OF TH1-LIKE REGULATORY T CELLS - A unique CD4 | 05-19-2016 |
20160136268 | MAMMALIAN MILK OSTEOPONTIN FOR ENHANCING IMMUNE RESPONSIVENESS - The disclosed invention provides mammalian milk osteopontin and/or an active truncation or active peptide thereof for improving immune responsiveness to an infectious disease in a mammal, for example a human subject, as well as enhancing the efficacy of vaccination for the prophylactic or therapeutic treatment of an infectious disease in mammals, such as humans. The invention further provides a vaccine system, for use in the prophylactic or therapeutic treatment of an infectious disease in a mammal, comprising a vaccine and a mammalian milk osteopontin and/or an active truncation or active peptide thereof for oral administration to a mammal, as well as methods of enhancing immune resistance to an infectious disease in a mammal by administration of a vaccine and a mammalian milk osteopontin and/or an active truncation thereof. | 05-19-2016 |
20160137696 | Immunomodulators - The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases. | 05-19-2016 |
20160138106 | Circulating Non-coding RNA Profiles for Detection of Cardiac Transplant Rejection - The level of miRNAs in a sample from a patient who has received a transplant is assayed and used as an indicator for transplant rejection. Based on the measured level of the miRNAs, therapeutic intervention, such as an immunosuppressant therapy, may be started, adjusted, continued or discontinued. | 05-19-2016 |
20160151485 | POLYSACCHARIDE SUITABLE TO MODULATE IMMUNE RESPONSE | 06-02-2016 |
20160152983 | NOVEL RIG-I LEGANDS AND METHODS FOR PRODUCING THEM | 06-02-2016 |
20160158346 | FUCOSYLLACTOSE AS BREAST MILK IDENTICAL NON-DIGESTIBLE OLIGOSACCHARIDE WITH NEW FUNCTIONAL BENEFIT - The invention concerns nutritional compositions with fucosyllactose for use in stimulation of NK cells. The composition is suitable for infants. | 06-09-2016 |
20160158349 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS - The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases. | 06-09-2016 |
20160161499 | SENSITIVE DIAGNOSTIC ASSAY FOR INCLUSION BODY MYSITIS - Assay methods, kits and systems for an improved sensitive diagnosis of inclusion body myositis (IBM) are provided. Assays, kits and systems involve detecting the presence and/or level of a combination of more than one autoantibody isotypes that are reactive against a cytosolic 5′-nucleotidase 1A protein (CN1A), or a cytosolic 5′-nucleotidase 1B protein (CN1B), or a CN1B isoform thereof, or a peptide fragment thereof, an isolated peptide thereof or a fusion protein comprising an isolated peptide of CN1A or CN1B. IBM patients have differing patterns of anti-cN1A/cN1B autoantibody isotypes. Therefore, testing a combination of such isotypes provide an improved and sensitive diagnostic assay. | 06-09-2016 |
20160166683 | ADJUVANT IMMUNOTHERAPY FOR THE TREATMENT CANCER, OF CLINICAL MANIFESTATIONS ASSOCIATED WITH THE DISEASES LIKE CACHEXIA AND CORRECTION OF ADVERSE EFFECTS OF DRUGS SUCH AS IMMUNOSUPPRESSION, SECUNDARY CACHEXIA, NEUTROPENIA AND LYMPHOPENIA, COMPRISING THE ASSOCIATION OR COMBINATION OF A BIOLOGICAL RESPONSE MODIFIER SPECIALLY SELECTED AND OTHER SUBSTANCES WITH ANTINEOPLASTIC ACTION AND/OR OTHER TREATMENTS | 06-16-2016 |
20160168571 | CpG-OLIGODEOXYNUCLEOTIDE, IMMUNOGENIC COMPOSITION COMPRISING THE SAME, AND METHODS FOR PREPARING THE COMPOSITION AND STIMULATING IMMUNE RESPONSE THEREBY | 06-16-2016 |
20160176928 | Immunomodulators | 06-23-2016 |
20160184376 | Method for Promoting ATP Production and Mitochondrial Activity, and Immunostimulating in Type 2 Diabetic Patients - An object of the present invention is to confirm the safety of a fermented papaya preparation in type 2 diabetic patients while determining its effect on ATP production and mitochondria to find further health advantages for type 2 diabetic patients. The present invention provides an ATP production promoter for promoting ATP production in type 2 diabetic patients and a mitochondrial activity promoter for promoting mitochondrial activity in the patients, each comprising a fermented papaya product as an active ingredient. The present invention also provides an immunostimulant for type 2 diabetic patients, based on promoting ATP production and/or mitochondrial activity in type 2 diabetic patients, comprising a fermented papaya preparation as an active ingredient. | 06-30-2016 |
20160184377 | Method for Promoting Respiratory Burst Activity Promoter and Immunostimulating in Type 2 Diabetic Patients - To confirm the safety of a fermented | 06-30-2016 |
20160184410 | TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE II - Methods of treating glycogen storage disease type II, by administering acid α-glucosidase, are described, as are compositions for use in treatment of glycogen storage disease type II. | 06-30-2016 |
20160184427 | QUIL A FRACTION WITH LOW TOXICITY AND USE THEREOF - Fraction A of Quil A can be used together with at least one other adjuvant for the preparation of an adjuvant composition, where the included adjuvant components act synergistically to enhance level of immune response and have synergistic immunomodulating activity on the co-administered antigens or immunogens. Other adjuvants can comprise saponins, naturally occurring, synthetic or semisynthetic saponin molecules; e.g. saponins and saponin fractions from Quil A, cell wall skeleton, block polymers, TDM, lipopeptides, LPS and LPS-derivatives, Lipid A from different bacterial species and derivatives thereof, e.g., monophosphoryl lipid A, CpG variants, CT and LT or fractions thereof. | 06-30-2016 |
20160193350 | Phosphorylcholine Conjugates and Uses Thereof | 07-07-2016 |
20160194359 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | 07-07-2016 |
20160199439 | Application of recombinant immunoregulatory protein of ganoderma lucidum in preparation of drug for treating focal cerebral ischemia | 07-14-2016 |
20160199499 | USES OF PHOSPHOLIPID CONJUGATES OF SYNTHETIC TLR7 AGONISTS | 07-14-2016 |
20160200686 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | 07-14-2016 |
20160250305 | Method for Immunomodulation of using Aza-podophyllotoxin derivatives | 09-01-2016 |
20160376596 | COMPOSITIONS AND METHODS FOR INDUCING AN ENHANCED IMMUNE RESPONSE USING POXVIRUS VECTORS - Provided herein are recombinant poxviruses comprising heterologous or native nucleic acids specifying excess double-stranded RNA (dsRNA) early in infection, which may further comprise heterologous nucleic acids encoding one or more costimulatory molecules, and/or heterologous nucleic acids encoding one or more infectious disease-associated antigens or tumor-associated antigens, as well as pharmaceutical compositions comprising such recombinant poxviruses and methods and uses thereof. The recombinant poxviruses provided herein enhance innate and adaptive immune activation in subjects compared to identical recombinant poxviruses lacking heterologous or native transcription units specifying excess early dsRNA. | 12-29-2016 |
20170232022 | MIXTURE OF NON-DIGESTIBLE OLIGOSACCHARIDES FOR STIMULATING THE IMMUNE SYSTEM | 08-17-2017 |
20180022793 | CHEMOREPULSION OF CELLS | 01-25-2018 |
20190142935 | Formulation Containing TLR Agonist and Methods of Use | 05-16-2019 |
20220133885 | COMPOSITIONS AND METHODS EMPLOYING ADENOSINE DEAMINASE-1 (ADA-1) AS AN ADJUVANT - Compositions and methods incorporating Adenosine deaminase-1 (ADA-1) as an adjuvant. Polynucleotides encoding novel coding sequences, polypeptides, vectors containing same, and methods of use are provided. | 05-05-2022 |